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ABSTRACT

Author: Rolle-McFarland, Danelle, A. Doctor of Philosophy
Institution: Purdue University
Degree Received: December 2017
Title: Bone Manganese as a Potential Biomarker of Cumulative Manganese Exposure and Predictor
of Neurological Decline
Major Professor: Ellen Wells
Research into the health effects of cumulative exposure to manganese (Mn) has been
limited due to the lack of a biomarker that adequately represents cumulative exposure. In this
cross-sectional study, we assessed the usefulness of bone Mn (BnMn) as a biomarker of
cumulative Mn exposure and as an indicator of neurological decline. Our research group utilized
a novel, transportable, in vivo Neutron Activation Analysis (NAA) system to analyze BnMn in a
group of Chinese workers (N=60).
In addition to bone, blood and fingernail samples were also collected from participants
and analyzed for Mn. Participants completed a questionnaire that included work history and
demographic information as well as a battery of cognitive, motor, and olfactory tests. Using
participants’ work history, a cumulative exposure index (CEI) was created to represent longterm, occupational Mn exposure. Years of Mn exposure (MnYears) were also determined from
participants work history. The relationship between BnMn and 1) Mn exposure variable (CEI
and MnYears), 2) blood Mn (BMn), and 3) fingernail Mn (FMn) were assessed to investigate
which biomarkers were more strongly associated with BnMn. The relationships between blood,
fingernail, and bone Mn and the battery of cognitive (Animal Naming, Fruit Naming,
UCLA/WHO Audio Verbal Listening Test (AVLT)), olfactory (University of Pennsylvania
Smell Identification Test (UPSIT)), and motor (Purdue Pegboard, CATSYS Motor System) tests

xiii
were also assessed to investigate which biomarker was most sensitive to changes in neurological
function.
Median (interquartile range) BMn, FMn and BnMn were 14.1 (4.0) g/L, 6.1 (39.8) g/g,
and 2.6 (7.2) g/g respectively. In regression models adjusted for age and education, BnMn was
significantly associated with increased FMn (=1.38; 95% confidence interval (CI)=0.75, 2.00), Mn
CEI over the past 15 years (MnCEI15 ) (=5.33; 95% CI=2.07, 8.59) and Years of Mn exposure over
the past 15 years (MnYears15 ) (=1.73; 95% CI=0.17, 3.30), but not other measures. In regression
models adjusted for age, education and current factory of employment, BnMn was significantly
associated with decreasing average AVLT scores over the first 5 trials [ (95% CI) = -0.6 (-1.2, 0.09)] along with decreasing Animal Naming scores [ (95% CI) = -1.5 (-3.0, -0.7)]. FMn was also
significantly associated with decreases in average AVLT scores [ (95% CI) = -0.4 (-0.7, -0.03))] as
well as decreases in a difference in AVLT scores [ (95% CI) = -0.4 (-0.7, -0.02)]. BMn was not
significantly associated with any test scores. Out of the three Mn biomarkers, BnMn was the greater
predictor of decreasing function in 5 out of the 9 scores. Continuous ln(BnMn) was associated with
several CATSYS outcomes such as decreasing Rhythmic P/S fast (Non-dominant hand) (β = -0.019;
95% C.I. = -0.036, -0.002), decreasing Rhythmic F-Tap fast (Non-dominant hand) (β = -0.027; 95%
C.I. = -0.045, -0.008), increasing Center frequency (Dominant hand) (β = 0.443; 95% C.I. = 0.029,
0.858), and increasing tremor intensity (β = 0.011; 95% C.I. = 0.0001, 0.022).
Overall these results suggest BnMn could be a useful biomarker of cumulative Mn exposure
over the span of the past 15-16 years. They also demonstrate the association of BnMn with cognitive
and motor outcomes.
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CHAPTER 1. INTRODUCTION AND BACKGROUND

1.1 Manganese
Manganese (Mn), the twelfth most abundant metal in the biosphere, is an essential element that
can be found in various foods including nuts, cereals, legumes and green leafy vegetables (Skinner
1931). Mn is required for many processes in the human body and the main route of intake is through
dietary intake. However, there is currently no recommended dietary allowance for the metal
(Aschner and Aschner 2005). The National Academy of Sciences established an adequate intake
level due to the lack of an estimated average requirement value (Aschner and Aschner 2005; Institute
of Medicine (U.S.) 2001). Adults should consume between 2 – 5 mg of Mn daily with males
consuming more than females (2.3 vs 1.8 mg/day) (Aschner and Aschner 2005; Greger 1998). There
is a tolerable upper intake level of 11 mg/day not to be exceeded by healthy adults (Institute of
Medicine (U.S.) 2001).
1.1.1

Biological Role of Manganese

Within the body, Mn is required for several processes including bone formation as well as
amino acid, lipid, protein, cholesterol and carbohydrate metabolism (Aschner and Aschner 2005;
Institute of Medicine (U.S.) 2001). Mn can function as a key component of important
metalloenzymes including arginase (a cytosolic enzyme responsible for urea formation), pyruvate
carboxylase (an enzyme that catalyzes the first step of carbohydrate synthesis from pyruvate), and
manganese-superoxide dismutase (MnSOD) (a metalloenzyme that is essential in the body’s free
radical defense system) (Sigel and Sigel 2000).
Mn can also act as an enzyme activator for various enzymes including oxidoreductases
(enzymes that catalyze the transfer of electrons between molecules), transferases (enzymes that
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catalyze the transfer of a particular group from one molecule to another), hydrolases (enzymes that
catalyze the hydrolysis of a chemical bond), lyases (enzymes that catalyze the joining of specified
molecules or groups by a double bond), isomerases (enzymes that catalyze the conversion of a
specified compound to an isomer), and ligases (enzymes that cause ligation of DNA or another
substance) (Aschner and Aschner 2005; Sigel and Sigel 2000). Mn can non-specifically activate
these enzymes by either binding to the protein or causing a conformational change or by directly
binding to the substrate. (Sigel and Sigel 2000).
Mn an also act as an activator for Mn-specific enzymes. These include glycosyltransferases
(enzymes that catalyze the formation of glyosidic linkages to form glycosides), phosphoenolpyruvate
carboxykinase (PEPCK) (the enzyme that catalyzes the conversion of oxaloacetate to
phosphonolpyruvate, GDP, and CO 2 ), and glutamine synthetase (an enzyme found in high
concentrations in the brain that catalyzes the reaction of ammonia, glutamate, and ATP to glutamine,
ADP and phosphorus) (Sigel and Sigel 2000).
1.1.2

ADME of Manganese

There are several routes of exposure through which Mn can enter the body. One of the
primary routes of exposure is through ingestion. Mn can be ingested through the consumption of
Mn-rich foods like nuts, leafy vegetables, and tea. There is currently no Estimated Average
Requirement for Mn, however Adequate Intake (AI) values of 1.8 mg (for females age 19 and older)
and 2.3 mg (for men age 19 and older) have been set based on median intakes reported from the
Food and Drug Administration (IOM 2001). Individuals can ingest larger amounts of Mn through
the consumption of environmentally contaminated food and water. Other routes of exposure to Mn
include inhalation of airborne Mn, dermal absorption (Oliveira and Machado-Neto 2003), absorption
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through olfactory neurons in the olfactory (Tjälve et al. 1996), and intravenous injection of Mn
containing drugs (Sikk et al. 2011).
Once in the body, Mn is absorbed through the gastrointestinal tract or the lungs (Nadaska et
al. 2012). Previous research has shown that between 1-5% of ingested Mn is absorbed into the
gastrointestinal tract (Davidsson et al. 1988; Finley et al. 1994). Once in the body, Mn is not
metabolized. Instead, it primarily accumulates in the liver (1.2-1.3 mg/kg), brain (0.15-0.46 mg/kg),
and bone (up to 43% of body burden) (Krebs et al. 2014; Liu et al. 2014; Rahil-Khazen et al. 2002;
Subramanian and Meranger 1985). Mn exists in the body in several oxidative states, primarily
existing as Mn2+ or Mn3+. Intracellularly, Mn2+ exists in several complexes with compounds such as
bicarbonates and citrates as well higher-massed species such as albumin and β-globulin (Harris and
Chen 1994; Reaney et al. 2002). Since Mn ions have similar physiochemical properties as iron and
can compete with the metal during absorption, the majority of Mn3+ ions in the blood are bound to
transferrin, an iron-binding blood plasma glycoprotein (Michalke and Fernsebner 2014; RossanderHultén et al. 1991). Mn ions can also be transported throughout the body using other transporters
such as the divalent metal transporter 1 (DMT-1), the divalent metal/bicarbonate ion symporters
ZIP8 and ZIP14, various calcium channels and the SLC39 family of Zn transporters (Au et al. 2008;
Michalke and Fernsebner 2014).
Mn is primarily excreted from the body through biliary excretion although Mn can also be
excreted through urine, breast milk, and sweat (Reiman and Minot 1920; Omokhodion and Howard
1994). Mn can have a different biological half-life (t1/2 ) depending on the bodily tissue being
discussed. In some regions of the rat brain, the t1/2 was between 51 – 74 days with the hypothalamic
nuclei and thalamus containing Mn the longest (Takeda et al. 1995). In structures such as the
amygdala, hippocampus, and globus pallidus, Mn t1/2 can range between 5 – 7 days (Grünecker et al.
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2013). Mn in the liver and kidneys has a quicker clearance than in the brain (Drown et al. 1986) and
bone Mn has a much slower t1/2 of approximately 8.6 years in humans (O’Neal et al. 2014).
1.2 Manganese Exposure
Manganese overexposure can occur both environmentally and occupationally. The Tolerable
Upper Limit (TUL) for dietary Mn exposure is 11 mg/day for adults age 19+ (USLOM 2017). The
legal occupational exposure ceiling set by The Occupational Safety and Health Administration is 5
mg/m3 (NIOSH 2014). The American Conference of Governmental Industrial Hygienists (ACGIH)
regulatory body has an even more stringent occupational threshold value limit (TLV) of 0.02 mg/m3
which is a time-weighted average (TWA) value (NIOSH 2014). Overexposure can be defined as Mn
concentrations above these dietary and/or occupational limits.
1.2.1

Environmental Exposure

Environmental overexposure to Mn can occur through various ways. Mn is a naturally
occurring element and can be found in the environment in the soil, eroded rocks, and decomposed
plants (O’Neal and Zheng 2015). Human activities also play a major role in environmental Mn
exposure. Individuals can be exposed to airborne Mn due to living near factories that utilize Mn as a
product (Haynes et al. 2010; Kim et al. 2011; Mergler et al. 1999). Municipal groundwater can also
be a source of Mn exposure due to the leaching of Mn-containing materials in the water (eg. rocks,
minerals) (Bouchard et al. 2011; Groschen et al. 2008). Environmental Mn exposure can also occur
due to the combustion of Methylcyclopentadienyl manganese tricarbonyl (MMT), an anti-knocking
agent used in gasoline (Zayed et al. 1999). Pesticides and fungicides can also be sources of
environmental Mn exposure. Increased symptoms of Mn intoxication has been seen among
individuals exposed to the Mn-containing fungicide Maneb (Ferraz et al. 1988). Maneb has also been
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associated with increased risk of developing Parkinson’s disease (PD) (Costello et al. 2009).
Another potential source of environmental Mn exposure is its use in imaging techniques such as
Manganese-enhanced MRI (Silva et al. 2004). One drawback to the use of this technology is Mn’s
cellular toxicity (Silva et al. 2004).
1.2.2

Occupational Exposure

According to the International Manganese Institute approximately 17.1 million tons of Mn
was produced to be used industrially in 2011 (IMnI 2014). There are several industrial uses of Mn.
Mn is primarily utilized as an alloying element in the production of iron and steel but can also
sometimes be used as a sulfide forming agent as well as a deoxidizer (IMnI 2014). Mn can also act
as an alloying element in production of aluminum and copper (IMnI 2014). Mn is also industrially
used in the manufacturing of dry cell batteries, glass and ceramics, the fuel additive MMT, and
pesticides (Santamaria 2008).

Individuals involved in occupations such as mining, welding,

smelting, ore-processing, ferroalloy steel production, dry-cell battery manufacturing, and pesticide
manufacturing are at the greatest risk of occupational Mn exposure (Ferraz et al. 1988; Chia et al.
1993; Bader et al. 1999; Lucchini et al. 1999; Myers et al. 2003; Bowler et al. 2006; Cowan et al.
2009a). Individuals occupationally exposed to Mn can sometimes be exposed to concentrations
approximately 20,000 times higher than environmental concentrations (ATSDR 2015).
1.3 Manganese Toxicity
Over exposure to Mn can be toxic to several systems and organs within the body. An individual’s
susceptibility to Mn can be dependent on several factors. Age is an important consideration in Mn
susceptibility. For example, the young are at greater risk for Mn exposure due to increased intestinal
Mn absorption, increased permeability of Mn to neuronal barriers, and decreased biliary excretion
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capacity (Aschner and Aschner 2005; Cahill et al. 1980; Michalke and Fernsebner 2014; O’Neal and
Zheng 2015; Vorhees et al. 2014). Gender also plays a role in Mn susceptibility. Women, especially
pregnant women, absorb more Mn than men (Oulhote et al. 2014; Zhang et al. 2015).
1.3.1

Mn-induced Neurotoxicity

Mn exposure has been previously associated with neurotoxic effects including behavioral
changes, decreased cognitive function, and decreased motor function. Emotional changes, mania,
sleep disturbance, changes in eating habits, and sexual disturbances have all been associated with
Mn exposure (Cotzias 1958; Rodier 1955). These behavioral changes, also known as “Manganese
Madness” can lead to violence, criminal acts, and a state of mental excitement (Barceloux 1999;
Werbach 1992). In a group of rats exposed to Mn for 30 days, researchers saw increased
hyperactivation and fighting scores due to increased striatal dopamine and norepinephrine levels
(Chandra 1983).
Neurotoxic effects of Mn can also include decreased cognitive function. For example, when
compared to non-exposed controls, a group of former ferro-Mn and silico-Mn exposed production
plan workers reported more frequent symptoms of memory loss and fatigue (Bouchard et al. 2008).
Confined space bridge welders saw a 10-12-point decrease in IQ scores due to continued exposure to
Mn fumes (Bowler et al. 2007). In a study utilizing the Montreal Cognitive Assessment test of
visuospatial function, memory, attention, and delayed recall, Mn-exposed smelters had significantly
lower scores when compared to non-exposed controls (Zou et al. 2014).
Mn toxicity can also result in decreased motor function. A group of highly exposed Chinese
smelters had significantly lower Purdue Pegboard manual dexterity scores when compared to lowerexposed smelters as well as non-exposed controls (Cowan et al. 2009b). Swedish welders, no longer
exposed to Mn, had worse grooved pegboard scores when compared to the non-exposed referent
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group suggesting worse motor speed and manual dexterity (Wastensson et al. 2012). In cases of
acute high exposure or chronic low-level Mn exposure, the motor disorder Manganism can develop.
Manganism is similar to but distinct from idiopathic Parkinson’s disease due to different pathology.
Symptoms of the disorder include rigidity, slowness of movement (bradykinesia), resting tremor,
affected gait, and involuntary muscle contraction (dystonia) (Calne et al. 1994).
The exact mechanism by which Mn induces these behavioral, cognitive, and motor changes
is not fully understood. Some animal studies have suggested that unlike PD, dopaminergic neurons
in the substantia nigra and striatum are intact after Mn intoxication (Guilarte 2011; O’Neal and
Zheng 2015). It is therefore believed that the effects of Mn are due to changes in neurotransmission
instead of neuronal loss. Previous studies have shown an increase in dopamine and dopamine
metabolite levels in the striatum, substantia nigra, and hippocampus of Mn-exposed rats (Gwiazda et
al. 2007; Racette et al. 2012). Increased thalamic GABA levels have also been associated with Mn
exposure (Long et al. 2014).
1.3.2

Mn-induced Toxicity of Other Organs

Aside from the neurotoxic effects of Mn, other organs and systems are affected by Mn
exposure. Mn is highly concentrated in the mitochondria of cells so organs high in mitochondria like
the liver and kidney tend to have higher concentrations of Mn and are therefore greatly affected by
the metal (Huang and Lin 2004). Cases of severe Mn poisoning have been associated with acute
hepatic necrosis leading to hepatic failure as well as renal impairment including decreased creatinine
clearance and acute renal failure. (Huang and Lin 2004). Cardiovascular toxicity has also been
associated with Mn intoxication. Overexposure to Mn can lead to inhibition of myocardial
contractions, increased dilation of blood vessels, and can induce hypotension (O’Neal and Zheng
2015). Mn can also lead to increased heart rates and shorter P-R intervals (Jiang YM 2000).
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1.4 Manganese Biomarkers
A biological marker, or “biomarker”, is defined as any substance that can be measured in the
body to predict the incidence of an outcome or disease (WHO 2001). There are currently several
biomarkers that have been used to help identify both the high-levels of Mn associated with
occupational exposures as well as the low-levels of Mn associated with environmental exposures
(O’Neal and Zheng 2015). Having a biomarker that can adequately detect changes in exposure, even
at low, constant levels, is important as it will aid in detecting Mn levels before any irreversible
impacts of Mn toxicity can occur (O’Neal and Zheng 2015).
Blood Mn (BMn) has been suggested as a good indicator of recent Mn exposure. However,
increased variability of BMn, due to factors such as a short Mn half-life (t1/2 ), results in a poor
relationship between BMn and external Mn levels (Smith et al. 2007). Urine Mn (UMn) also has a
poor relationship with external Mn levels due to the small amounts of Mn found in urine (Smith et
al. 2007). This is because Mn is primarily excreted out of the body in fecal matter.
A recent study assessed the usefulness of metabolite ions in urine as a biomarker of Mn
exposure (Baker et al. 2017). Researchers found that 9 metabolites were able to significantly
distinguish between exposure groups, however these metabolites were not identified and could
possibly be non-specific to the Mn exposure (Baker et al. 2017). Further work is necessary to
develop metabolomics as a useful biomarker of Mn exposure. Hair Mn (HMn) and toenail Mn
(TMn) have both shown association with external Mn levels (Bader et al. 1999; Laohaudomchok et
al. 2011) However, the lack of a rapid process to remove external contamination and the variability
associated with these biomarkers limits their utility (Bader et al. 1999).
The Mn/Fe ratio (MIR) in erythrocytes (eMIR) and plasma (pMIR) has been suggested as a
biomarker of Mn exposure as well (Cowan et al. 2009a). Both eMIR and pMIR concentrations
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significantly reflected external air Mn concentrations in an occupational setting, however their utility
to reflect environmental exposure still needs to be assessed (Cowan et al. 2009a; O’Neal and Zheng
2015). Saliva (SMn) has also been used as a biomarker of Mn exposure and has been able to
distinguish exposed individuals (Wang et al. 2008). However, the reliability of the biomarker is
questioned due to the large variation in concentrations. (Wang et al. 2008).
Non-invasive imaging techniques have also been assessed for their usefulness as a biomarker of
Mn exposure. T-1 weighted magnetic resonance imaging (MRI) has been used to assess Mn
exposure in a group of welders (Kim 2004). Increased signals were prevalent in Mn-exposed
workers and the concentrations required for these increased signals were lower than Mn
concentrations necessary for clinical Manganism (Kim 2004). One limitation of the MRI was that
the signals decreased once the individual was removed from the Mn source suggesting it may only
be useful for recent exposures (Kim 2004). Magnetic resonance spectroscopy was also used to assess
GABA concentrations in Mn exposed smelters (Dydak et al. 2011). Similarly to MRI, there were T1hyperintense signals in the MRS where Mn accumulated. The Mn concentrations that produced these
signals were yet again low levels suggesting that MRS could be useful in detecting Mn-induced
deficits before clinical Manganism occurs (O’Neal and Zheng 2015).
1.5 Bone Manganese Study
This cross-sectional study was aimed at assessing bone Mn (BnMn) in a group of 60 Chinese
male workers from a local ferroalloy and a local manufacturing factory in Zunyi, China. Our
research team developed a novel transportable in vivo Neutron Activation Analysis system (IVNAA)
capable of non-invasively quantifying BnMn in individuals’ hand bones (Liu et al. 2013). IVNAA is
an established analytical technique that is used to quantitatively measure elements in a sample
(Corliss 1968). Using a deuterium-deuterium neutron ion source, the IVNAA system excites with the
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55Mn neutrons in the hand bones of study subjects. During the radioactive decay of the unstable
56 Mn

excited neutrons to stable

56 Fe

neutrons, characteristic γ-rays are produced (847 keV). The γ-

rays are counted to give a Mn count. These counts are calcium normalized to account for differences
between subjects such as the thickness of the soft tissue of everyone’s hand or the slightly different
irradiation geometrics per person. Calcium is used since it is relatively constant in bone.
1.5.1

Significance

Mn research is focused on identifying Mn biomarkers that can help to identify early-stage
impacts of Mn toxicity (O’Neal and Zheng 2015; Zheng et al. 2011). As previously mentioned, there
are several biomarkers of Mn exposure, none of which adequately describe Mn body burden. BnMn
has been suggested as a useful, non-invasive biomarker of cumulative Mn exposure that can help to
alleviate some of the major limitations associated with existing Mn biomarkers that make them
inadequate in describing cumulative exposure. BnMn appears to be a better indicator of Mn body
burden as approximately 40% of Mn in the body is stored in bone (Liu et al. 2013). BnMn is also
potentially a useful biomarker of cumulative exposure as the biological t 1/2 of Mn in bone is ~ 8-9
years thus representing cumulative exposure (O’Neal 2014). BnMn has also been associated with
Mn concentrations in the striatum, hippocampus, and cerebral spinal fluid (O’Neal 2014). This
suggests that BnMn could be reflective of Mn concentrations in the brain which could be crucial in
understanding neurotoxic effects of Mn exposure.
The location of this study is also important. This study was conducted in Zunyi, China, a city
in the Southwestern Province of Guizhou. China is the world’s largest producer of Mn (IMnI 2014).
Zunyi is one of the major industrial hubs in the region with smelting, aluminum and titanium
processing, and coal mining being some of the major industrialized facilities in the region (Cowan
2008).
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1.5.2

Specific Aims and Hypotheses

The overall hypothesis of this study was that BnMn is a biomarker of cumulative Mn
exposure and is associated with cognitive, motor, and olfactory function decline.

To assess this

hypothesis, three specific aims where developed. Aim 1 was to describe the distribution and
predictors of bone Mn levels among occupationally exposed male smelters and non-occupationally
exposed male workers using the novel transportable IVNAA system. We hypothesized that the
occupationally exposed males would have higher BnMn concentrations than the non-occupationally
exposed males. Aim 2 was to assess the correlation between BnMn and 1) an occupational Mn
cumulative exposure index (MnCEI), 2) fingernail Mn (FMn), and 3) blood Mn (BMn), of
occupationally and non-occupationally Mn exposed male workers. We hypothesized that BnMn
would be more strongly associated with the CEI (a measure of cumulative exposure spanning years)
than either the FMn or BMn (measures of Mn exposure spanning days – months). Aim 3 was to
determine the association between the 3 Mn biomarker concentrations (BMn, FMn, and BnMn) and
the cognitive, olfactory, and motor tests scores of occupationally and non-occupationally exposed
male workers. We hypothesized that BnMn would be a better predictor of impaired performance on
these tests than FMn or BMn.
1.5.3

Dissertation Structure

Subsequent chapters of this dissertation will describe how these aims were met in depth.
Chapter 2, which focuses on aim 1, will describe the overall study methods as well as BnMn, FMn,
and BMn concentrations for the study population. In this chapter, detailed demographic information
will be provided and predictors of BnMn, FMn, and BMn will be discussed. Chapter 3 will discuss
the methods, results and conclusions specific to aim 2. In this chapter, more detailed information will
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be provided on the creation of the MnCEI as well as the association between BnMn and the
measures of Mn exposure.
Chapters 4 and 5 will detail the methods, results and conclusions specific to aim 3. Chapter 4
will focus on the cognitive and olfactory tests used in this study whereas chapter 5 will focus on the
motor tests. These chapters will describe the association between al 3 Mn biomarkers and test
outcomes. Chapter 6 will provide an overall summary of the study as well as possible future
directions for this work.
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CHAPTER 2. ASSESSMENT OF BONE MN (BNMN) DISTRIBUTION IN
AN OCCUPATIONAL POPULATION

Abstract
Objective: Neurotoxicity of chronic manganese (Mn) exposure is not well understood partly due to
the lack of a quantitative biomarker of cumulative Mn exposure. Bone Mn (BnMn) may be a useful
cumulative biomarker.

This describes bone Mn (BnMn), blood Mn (BMn), and fingernail Mn

(FMn) in an occupational population.
Methods: An In Vivo Neutron Activation Analysis system was used to quantify BnMn in a crosssectional study of 60 male Chinese ferroalloy and manufacturing workers. BMn and FMn were
measured using inductively coupled plasma mass spectrometry. Demographic and occupational
history information were collected using a questionnaire. Associations between Mn biomarkers and
demographic variables were evaluated using linear regression models.
Main Results: Median (interquartile range) BMn, FMn and BnMn were 14.1 (4.0) g/L, 6.1 (39.8)
g/g, and 2.6 (7.2) g/g respectively.

ln(BnMn) was significantly correlated with working at the

ferroalloy factory (β = 0.17; p = 0.02). However, years in current occupation, age, drinking tea
weekly (compared to daily), eating rice once/day (compared to 2-3 times a day), welding, working
with Mn ore, working with paints, and working with solvents all produced non-significant increases
in lnBnMn.
Significance: Our results suggest that several known sources of Mn can contribute to BnMn
concentrations.
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2.1 Materials and Methods
Study Population
Sixty-one male workers from Zunyi, China were initially recruited for this cross-sectional
study. Thirty participants, presumed to have low/no occupational Mn exposure, were recruited from
a local manufacturing factory. Thirty-one participants, presumed to have high occupational Mn
exposure, were recruited from a ferroalloy factory. Individuals were excluded if they had any active
neurological or psychiatric disease, any known motor or cognitive impairment that was not directly
related to Mn exposure, or if they did not complete the BnMn measurement. One ferroalloy worker
was excluded from the study due to a lack of BnMn data, leaving 60 study participants for analyses.
The Purdue Institutional Review Board and Zunyi Medical College Ethical Review Board approved
this study. Participants signed an informed consent document prior to their participation.

Mn Biomarkers
Trained clinical staff collected whole blood samples from participants using standard
protocols. Trace metal-free vacutainers (Becton-Dickinson, USA) were used to limit external metal
contamination. Samples were frozen at -20 C and stored until analysis. Whole blood samples were
analyzed for Mn, using methods similar to prior studies (Ding et al. 2012, Zhang et al. 2015), at the
Chinese Centers for Disease Control and Prevention in Beijing using inductively-coupled mass
spectrometry (ICP-MS). Briefly, blood samples were diluted with 0.01% Triton-X-00 (SigmaAldrich, USA) and 0.5% ultrapure concentrated nitric acid (Merck, Darmstadt, Germany). Samples
were vortexed and then analyzed using XSERIES 2 ICP-MS (Thermo Fisher, USA. The
SeronormTM Trace Elements Whole Blood Control Level 1 (Sero AS, Billingstad, Norway) was
used for internal quality insurance. None of the collected samples had Mn concentrations below the
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detection limit (DL) of 0.11 g/L. A questionnaire was administered by study staff while the BnMn
measurement was being completed. This questionnaire included information on participants such as
age, education, marital status, work history, and dietary intake.
Due to observations that participants frequently wore open-toe shoes at work, toenails were
presumed to have substantial amounts of external contamination. Fingernails were therefore used
instead of the more commonly used toenails to determine nail Mn concentrations. Participants were
asked to thoroughly wash their hands with soap to remove external debris. Fingernail samples from
participants’ 10 fingers were collected using a titanium dioxide nail clipper. Fingernail samples were
stored in small Ziploc bags and kept at room temperature until analysis. Fingernail samples were
cleaned twice using ultrasonic cleaning procedures in 1% Triton X-100 solution (Sigma-Aldrich
Inc., USA) (Kile et al. 2007). Following each cleaning, nails were rinsed multiple times with
deionized (DI) water and then dried at 60 C. Once dried, fingernail samples were digested at 200 C
in ultrapure nitric acid (Sigma-Aldrich Inc., USA) then analyzed for Mn using ELEMENT-2 mass
spectrometer (ThermoFinnigan, Bremen, Germany) at Purdue University’s Campus-Wide Mass
Spectrometry. Mn concentrations were corrected for systematic error using an internal standard run
simultaneously with the samples. The DL for this method was 0.18 ppb. Three fingernail samples
(5%) were below the detection limit. A value of

was used as the Mn concentrations (ppb) in

these samples.
After fingernails were cut but prior to the BnMn measurement, participants were asked to
wash their right hand and lower arm with soap and water for a second time. To further reduce the
potential for external contamination, a trained research assistant also cleaned participants’ right hand
and lower arm with 50% alcohol wipes. Each participant’s right hand was irradiated for 10 minutes
to excite the

55 Mn

atoms in the hand bone to

56 Mn.

A bag filled with water was wrapped around the
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participant’s arm to hold it in place as well as reduce the whole body effective radiation dose
(estimated at 23 µSv) (Liu et. al 2013). Participants then moved to a high purity germanium (HPGe)
detection system that collected Mn γ ray (847 keV) spectra over the course of an hour as the

56 Mn

neutrons de-excite (Liu et al. 2013). BnMn concentrations were calculated from the Mn γ ray
spectra using a pre-existing calibration line created from a set of Mn-doped bone-equivalent hand
phantoms. A Mn/Ca γ ray ratio was used to account for variation in neutron flux, hand palm
attenuation, and counting geometry. The transportable IVNAA system has a DL of 0.64 µg Mn per
g bone (ppm) (Liu et al. 2017). There were 19 (31.7%) participants with BnMn < DL; 13 of the 19
(68.4%) were negative values. Negative BnMn measurements can be estimated when the true BnMn
value is close to zero: this has also been seen in bone lead measurements (Park et al. 2009). For bone
lead, it is recommended to include negative concentrations in analyses as this provides less bias and
greater efficiency in comparing measures of center when analyzing the bone data (Kim et al. 1995,
Park et al. 2009); therefore, we also retained all BnMn concentrations in analyses.

Statistical analyses
All statistical analyses were completed using Stata 13.1 (College Station, Texas, USA). A pvalue < 0.05 was considered statistically significant.
Bone Mn
A box plot of the untransformed BnMn concentrations (Figure 1) shows that the BnMn data
appears to be right skewed. The Skewness (1.70) and Kurtosis (4.94) values also suggest that the
data is not normally distributed. To further illustrate the right-skewness of the data, a histogram of
BnMn was created (Figure 2.). More than half of the study participants had BnMn concentrations
<10 g/g Ca (N=47).

17

Figure 1. Boxplot of Untransformed Bone Mn (BnMn) Concentrations

Figure 2. Histogram of Untransformed BnMn Concentrations
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To assess which transformation will allow the data to be more normally distributed, a
Tukey’s Ladder of Powers was performed (Table 1). The smallest χ2 value was 19.67; a value which
was still high. Also, due to the negative values of some of the bone measurements, χ 2 values for the
square root, inverse square root, and log transformations were not able to be assessed. Since square
root and log transformations are commonly used with right skewed data, a method to handle
negative BnMn values had to be utilized.
Table 1. Tukey's Ladder of Powers Results for BnMn (Before Translation)
Transformation

Formula

χ2

P(χ 2 )

Cubic

BnMn3

45.41

<0.01

Square

BnMn2

36.80

<0.01

Identity

BnMn

19.67

<0.01

.

.

.

.

.

.

Square root
Log

ln(BnMn)

1/ (square root)
Inverse

1/BnMn

58.40

<0.01

1/square

1/ BnMn2

70.70

<0.01

1/cubic

1/ BnMn3

73.47

<0.01

Atkins (1994) proposed the addition of a shift constant that would make all the negative
BnMn values positive, thus allowing for a log transformation. According to Atkins (1994), taking
the log of the data, after the addition of the shift constant, is sometimes indistinguishable from a
transformation that does not include the addition of a shift constant. The shift constant used with
BnMn measurements was 5.99 which would allow the equation ymin + constant = 1 to be true
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(Atkinson, 1994). This shift would not affect variance, therefore subsequent analyses would be
reflective of original BnMn concentrations prior to any translations or transformations.

Table 2. Tukey's Ladder of Powers results on BnMn concentrations (After Translation)
Transformation
Formula
χ2
P(χ 2 )
Cubic

BnMn3

42.17

<0.01

Square

BnMn2

33.28

<0.01

Identity

BnMn

19.67

<0.01

10.24

<0.01

0.87

0.06

24.94

0.01

Square root
Log

ln(BnMn)

1/ (square root)
Inverse

1/BnMn

52.30

<0.01

1/square

1/ BnMn2

.

<0.01

1/cubic

1/ BnMn3

.

<0.01

Another Tukey’s Ladder of Powers was calculated on the shifted BnMn concentrations
(Table 2). This time, there were χ

2

values for the square root, inverse square root and log

transformations. Although the probability was not significant, the log square transformation seemed
to be the best option to transform the BnMn into a more normally distributed population. This can
also be seen in the graphs of the transformation of the data (Figure 3). As a result, natural log
transformed BnMn was used in subsequent analyses.
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Figure 3. Histogram plots of Shifted Bone Mn Concentrations by Transformation

Fingernail Manganese

A box plot of the untransformed FMn concentrations (Figure 4) shows that the FMn data also
appears to be right skewed. The Skewness (3.64) and Kurtosis (17.76) values also suggest that the
data is not normally distributed. To further illustrate the right-skewness of the data, a histogram of
FMn was also created (Figure 5). Approximately 85% of the study participants had FMn
concentrations <100 g/g (N=51).

21

Figure 4. Boxplot of Untransformed Fingernail Mn (FMn) Concentrations

Figure 5. Histogram of Untransformed FMn Concentrations
A Tukey’s Ladder of Powers was performed for the FMn concentrations as well (Table 3).
The cubic and square transformations could not be completed on the FMn concentrations. Although
all the other transformations produced significant χ

2

values, the smallest χ

2

was for the natural log
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transformation (5.13) suggesting that would be the best transformation for a more normal
distribution. This can also be seen in the graphs of the FMn transformation (Figure 6). As a result,
natural log transformed FMn was used in subsequent analyses.

Transformation

Table 3. Tukey's Ladder of Powers results for FMn
Formula
χ2

P(χ 2 )

Cubic

FMn3

.

.

Square

FMn2

.

.

Identity

FMn

51.83

<0.01

27.01

<0.01

5.13

0.08

17.30

<0.01

Square root
Log

ln(FMn)

1/ (square root)
Inverse

1/FMn

37.23

<0.01

1/square

1/ FMn2

54.17

<0.01

1/cubic

1/ FMn3

61.59

<0.01

23

Figure 6. Histogram Plots of Shifted Fingernail Mn Concentrations by Transformation

Blood Manganese

A box plot of the untransformed BMn concentrations (Figure 7) shows that the BMn data
also appears to be right skewed. The Skewness (2.61) and Kurtosis (14.46) values also suggest that
the data is not normally distributed. To further illustrate the right-skewness of the data, a histogram
of BMn was created (Figure 8). Approximately 85% of the study participants had FMn
concentrations <100 g/g (N=51).
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Figure 7. Boxplot of Untransformed Blood Mn (BMn) Concentrations

Figure 8. Histogram of Untransformed BMn Concentrations
A Tukey’s Ladder of Powers was performed for the BMn concentrations as well (Table 4).
The cubic transformation could not be performed on the BMn concentrations. The 1/ (square root)
transformation had the smallest χ

2

value (1.83), however this value was not significant. The lowest

significant χ 2 value was for the natural log transformation (9.81). Looking at the graphs of the BMn
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transformation (Figure 9), the natural log transformation does produce a somewhat normal
distribution. Due to this fact, and to keep consistent with the other Mn biomarker concentrations,
natural log transformed BMn was used in subsequent analyses.

Transformation

Table 4. Tukey's Ladder of Powers results for BMn
Formula
χ2

P (χ 2 )

Cubic

BMn3

.

.

Square

BMn2

67.29

<0.01

Identity

BMn

40.83

<0.01

24.30

<0.01

9.81

0.01

1.83

0.40

Square root
Log

ln(BMn)

1/ (square root)
Inverse

1/BMn

2.91

0.23

1/square

1/ BMn2

11.63

<0.01

1/cubic

1/ BMn3

19.88

<0.01
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Figure 9. Histogram plots of Shifted Blood Mn Concentrations by Transformation
Means (standard deviations) and Medians (Interquartile Ranges) for all 3 Mn biomarkers,
before transformations, were reported for the entire population. Population characteristics were
reported for this study population. For continuous variables (Table 5) two-sample t-tests were used
to assess the statistical difference between means and Mann-Whitney tests were performed to assess
the statistical difference between medians. For categorical variables (Table 6) Pearson’s χ 2 test was
used to assess statistical difference between factories. Linear regression models were created to
assess which characteristics were independently associated with Mn biomarker concentrations.
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2.2 Results
Both Means (SD) and Median (IQR) of BMn, FMn, and BnMn are reported in Table 5. The
ranges of Mn biomarkers were 8.43 to 39.70 g/L for BMn, 0.15 to 935.65g/g for FnMn, and -5.00
to 43.02 g/g for BnMn. Mean and Median BMn as well as FMn were significantly different
between factories. Mean BnMn is significantly different between factories but not median BnMn.
However, median BnMn for the ferroalloy factory is almost 3 times that of the manufacturing
factory.
Table 6 reports potential predictors of the Mn biomarkers for the total population as well as
by factory. Most of the population were smokers (76.7%) and drinkers (73.3%). There were slightly
more smokers in the ferroalloy factory (83.3% vs. 70.0%) whereas the number of drinkers were
consistent between factories (N=22; 73.3 %). Approximately 90% of the population were married
and only 10% made more than 80,000 annually. Unsurprisingly, almost 100% of the population ate
rice 2-3 times a day Several of the occupational variables were significantly different between
factories (welding, working with Mn ore, and working with other metals).
The association between each predictor and the Mn biomarkers are reported in Table 7.
Increasing education was associated with decreasing ln(BnMn) (β = -0.02; p = 0.01) as well as
decreasing ln(FMn) (β = -0.16; p = 0.03). Working at the ferroalloy factory was significantly
associated with increasing ln(BnMn) (β = 0.17; p = 0.02) and increasing ln(FMn) (β = 3.69; p <
0.01). Several of the occupational predictors were significantly associated with FMn. Working with
Mn ore saw an increase in ln(FMn) (β = 1.94; p < 0.01) but working with other metals saw a
significant decrease in ln(FMn) (β = -2.31; p < 0.01). Increasing ln(BMn) was only associated with
increasing years in current occupation (β = 0.05; p < 0.01).

Characteristic
Age (years)
Education (years)
Years in Current Occupation

Table 5. Population Characteristics by Factory of Employment
Total
Manufacturing
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
47.4 (7.9)
48.5 (10.0)
48.2 (9.4)
51.0 (17.0)
10.0 (3.9)
10.0 (8.0)
10.9 (4.0)
11.0 (5.0)
9.0 (6.8)
8.0 (5.6)
9.5 (8.7)
5.5 (6.2)

Ferroalloy
Mean (SD)
Median (IQR)
46.7 (6.1)
46.0 (8.0)
9.1 (3.6)
9.0 (5.0)
8.4 (4.1)
9.0 (7.0)

Biomarker
14.5 (4.7)
14.1 (4.0)
BMn (g/L) a, b
a,
b
FMn (g/g)
67.4 (157.9)
6.1 (39.8)
a
BnMn (g/g)
7.1 (12.0)
2.6 (7.2)
N = 30 for manufacturing facility; N=30 for Ferroalloy facility; Total
BMn = Blood Manganese
FMn = Fingernail Manganese
BnMn = Bone
a = means significantly different between groups.
b = medians significantly different between groups.

13.2 (3.3)
2.6 (4.0)
3.9 (7.9)
N = 60

13.4 (26.1)
1.2 (3.6)
0.9 (4.5)

15.9 (5.6)
132.3 (205.0)
10.3 (14.4)

15.2 (5.9)
41.1 (116.2)
3.0 (16.3)

28

29
Table 6. Potential Predictors of Mn biomarkers by Factory of Employment
Total
Manufacturing
Ferroalloy
Characteristic
N (%)
Current Smoker
No
14 (23.3)
9 (30.0)
5 (16.7)
Yes
46 (76.7)
21 (70.0)
25 (83.3)
Current Drinker
No
16 (26.7)
8 (26.7)
8 (26.7)
Yes
44 (73.3)
22 (73.3)
22 (73.3)
Income
≤40,000
27 (45.0)
14 (46.7)
13 (43.3)
40,000 – 80,000
27 (45.0)
13 (43.3)
14 (46.7)
>80,000
6 (10.0)
3 (10.0)
3 (10.0)
Marriage Status
Divorced/Separated
3 (5.0)
2 (6.7)
1 (3.3)
Married
56 (93.3)
28 (93.3)
28 (93.3)
Never Married
1 (1.7)
1 (3.3)
Tea Drinking Frequency
Daily
40 (67.8)
23 (79.3)
17 (56.7)
Weekly
11 (18.6)
4 (13.8)
7 (23.3)
Monthly
8 (13.6)
2 (6.9)
6 (20.0)
Rice Eating Frequency
2-3 times/day
59 (98.3)
29 (96.7)
30 (100)
Once/day
1 (1.7)
1 (3.3)
Vegetable Eating Frequency
2-3 times/day
55 (91.7)
26 (86.7)
29 (96.7)
Once/day
5 (8.3)
4 (13.3)
1 (3.3)
a
Welding
No
26 (43.3)
9 (30.0)
17 (56.7)
Yes
34 (56.7)
21 (70.0)
13 (43.3)
Soldering
No
52 (88.1)
25 (83.3)
27 (93.1)
Yes
7 (11.9)
5 (16.7)
2 (6.9)
Smelting
No
54 (91.5)
26 (86.7)
28 (96.6)
Yes
5 (8.5)
4 (13.3)
1 (3.4)
a
Work with Mn Ore
No
32 (54.2)
24 (80.0)
8 (27.6)
Yes
27 (45.8)
6 (20.0)
21 (72.4)

30
Table 6. Continued
Work with Paints
No
Yes

34 (56.7)
26 (43.3)

15 (50.0)
15 (50.0)

19 (63.3)
11 (36.7)

No
Yes

42 (70.0)
18 (30.0)

21 (70.0)
9 (30.0)

21 (70.0)
9 (30.0)

Work with Solvents

Work with Other Metals

a

No
37 (62.7)
11 (36.7)
26 (89.7)
Yes
22 (37.3)
19 (63.3)
3 (10.3)
N = 30 for manufacturing facility; N=30 for Ferroalloy facility (29 for poor memory); Total N = 60
(59 for poor memory)
a = significantly different between groups.
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Table 7. β (p-value) from Regression Model Comparing each predictor to Mn Biomarkers
Mn Biomarker
Characteristic
ln(BMn)
ln(FMn)
ln(BnMn)
Age (years)
0.001 (0.77)
0.02 (0.60)
0.01 (0.33)
Education (years)
-0.02 (0.01) a
-0.16 (0.03) a
0.005 (0.87)
Years in Current Occupation
0.004 (0.41)
-0.007 (0.87)
0.05 (<0.01) a
Current Factory of Employment
Ferroalloy 0.17 (0.02) a
3.69 (<0.01) a
0.40 (0.08)
Current Smoker
Yes -0.14 (0.10)
0.61 (0.39)
0.29 (0.24)
Current Drinker
Yes -0.02 (0.77)
0.68 (0.31)
0.32 (0.17)
Income
40,000 – 80,000 -0.05 (0.53)
-0.05 (0.93)
-0.27 (0.23)
>80,000 -0.20 (0.10)
-0.08 (0.94)
-0.21 (-0.94)
Marriage Status
Divorced/Separated -0.29 (0.08)
-0.45 (0.74)
-0.12 (0.64)
Never Married -0.10 (0.72)
2.15 (0.36)
0.39 (0.64)
Tea Drinking Frequency
Weekly
0.16 (0.08)
0.73 (0.35)
-0.30 (0.29)
Monthly -0.04 (0.68)
0.83 (0.35)
-0.35 (0.27)
Rice Eating Frequency
Once/day
0.03 (0.92)
-1.43 (0.54)
1.03 (0.21)
Vegetable Eating Frequency
Once/day -0.08 (0.56)
-1.12 (0.29)
-0.22 (0.57)
Welding
Yes
0.11 (0.14)
-0.82 (0.17)
0.03 (0.90)
Soldering
Yes -0.05 (0.64)
-1.15 (0.22)
-0.31 (0.36)
Smelting
Yes -0.05 (0.69)
-1.97 (0.07)
-0.21 (0.60)
Work with Mn Ore
Yes
0.13 (0.07)
1.94 (<0.01) a
0.30 (0.20)
Work with Paints
Yes 0.002 (0.98)
-0.95 (0.11)
-0.29 (0.17)
Work with Solvents
Yes
0.07 (0.34)
-0.46 (0.48)
0.10 (0.36)
Work with Other Metals
Yes -0.06 (0.45)
-2.31 (<0.01) a
-0.34 (0.78)
Total N = 60
β (p-value)
a = significant at ≤0.05 level
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2.3 Discussion
Biomarkers such as blood, urine, and nails are useful as indicators of occupational Mn
exposure, but not necessarily cumulative occupational Mn exposure. However, BnMn maybe a
biomarker that adequately represents cumulative Mn exposure. To the best of our knowledge, to
date, this is the largest study to use an IVNAA system, particularly a transportable system, to assess
BnMn in an occupational population.
Median BnMn in our study was reported as 2.6 µg/g bone or 10.2 µg/g Ca when converted.
These values were higher than BnMn previously reported in our pilot study of Mn-exposed workers
and controls (0.66 µg/g dry bone) (Wells et al. 2018) as well as to mean BnMn of occupationally
exposed welders (2.9 µg/g Ca) reported by Pejović-Milić et al. (2009). There was a larger range of
BnMn in our study population (-5.0 to 43.0 g/g bone/ -19.7 to 169.4 µg/g Ca) than in the study of
welders and controls conducted by (-3.8 to 9.1 g/g Ca) Pejović-Milić et al. (2009) suggesting more
variance in our study population.
Both BMn and FMn concentrations in this study fell within ranges seen in previous studies.
Median BMn in this study (14.1 µg/L) fell within ranges of BMn (0-50 µg/L) previously reported in
other occupational studies (Baker et al. 2014; Wang et al. 1989). The median FMn of 6.1 µg/g is
similar to the median FMn concentration (6.9 µg/g) seen in an environmental study of two Brazilian
communities near ferromanganese facilities (Viana et al. 2014).
Working at the ferroalloy factory was significantly associated with increasing ln(BnMn).
Although not significant, years in current occupation, age, drinking tea weekly (compared to daily),
eating rice once/day (compared to 2-3 times a day), welding, working with Mn ore, working with
paints, and working with solvents all were associated with increases in ln(BnMn). Smoking and
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drinking were associated with increasing ln(FMn) and ln(BnMn) but not ln(BMn), although these
relationships were not significant.
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CHAPTER 3. IN VIVO NEUTRON ACTIVATION ANALYSIS OF BONE
MANGANESE: A POTENTIAL BIOMARKER OF CUMULATIVE MN
EXPOSURE

Abstract
Objective: Neurotoxicity of chronic manganese (Mn) exposure is not well understood partly due to
the lack of a quantitative biomarker of cumulative Mn exposure. Bone Mn (BnMn) may be a useful
cumulative biomarker. This analysis compares a novel, transportable, method to quantify bone Mn
(BnMn) with blood Mn (BMn), fingernail Mn (FMn), a Mn cumulative exposure index (MnCEI),
and years of Mn exposure (MnYears).
Methods: MnCEI and MnYears were calculated for the prior 15 years and total work history.
Associations between BnMn and other measures of Mn exposure were evaluated using Spearman
correlations and linear regression models adjusted for age and education.
Main Results:

BnMn was significantly correlated with FMn (Spearman’s ρ=0.44; p <0.01),

MnYears15 (ρ=0.32; p=0.01), and MnCEI15 (ρ=43; p <0.01); but not with BMn, MnCEIT OT , or
MnYearsT OT . In adjusted regression models, BnMn was significantly associated with increased FMn
(=1.38; 95% confidence interval (CI)=0.75, 2.00), MnCEI15 (=5.33; 95% CI=2.07, 8.59) and
MnYears15 (=1.73; 95% CI=0.17, 3.30), but not other measures. Results for models using a
continuous variable for Mn were similar
Significance: Our results suggest that BnMn could be associated with exposure over the past 15
years but possibly not lifetime exposure.
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3.1 Introduction
Manganese (Mn) is an essential metal used in many industrial settings, including mining,
welding, smelting, ore-processing, ferroalloy steel production, dry-cell battery manufacturing, and
pesticide manufacturing. Occupational overexposure to Mn can result in many negative health
outcomes including fatigue, postural tremor (Ferraz et al. 1988), decreased visuomotor coordination
(Chia et al. 1993), impaired memory functions (Bowler et al. 2006; Lucchini et al. 1999), deficits in
information processing and working memory (Bowler et al. 2006), olfactory impairment (Bowler et
al. 2007), and decreased motor function (Bowler et al. 2006; Cowan et al. 2009a; Cowan et al.
2009b).
Biomarkers are substances that can be measured in the body and can be used to quantify
exposure or health outcomes (WHO 2001). For biomarkers of Mn exposure to be advantageous in
research on the health impacts of Mn, they need to correlate with the clinical endpoint they reflect as
well as be consistent between studies (Strimbu and Tavel 2010). Existing biomarkers have been
shown to reflect Mn exposure over the past several days (blood Mn, urine Mn) (Cowan et al. 2009a;
Cowan et al. 2009b; Laohaudomchok et al. 2011; Järvisalo et al. 1992; Zheng et al. 2000) or months
(hair Mn, toenail Mn). Laohaudomchok et al. concluded that toenail Mn was reflective of external
Mn exposure in the prior 7-12 months among a group of welders (Laohaudomchok et al. 201). With
a growth rate of approximately 1-2 cm/month, depending on how much of a sample is collected, hair
Mn can be reflective of several months of Mn exposure (Eastman et al. 2013; Reiss et al. 2016).
These biomarkers have also been shown to distinguish between those with occupational
exposure vs. not. Blood Mn was found to be significantly elevated in a group of Italian ferroalloy
workers (Apostoli et al. 2000) and in a cross-sectional study of 96 Russian welders (Ellingsen et al.
2006) when compared to workers without known Mn exposure. In a study of San Francisco Bay
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bridge welders, active welders had significantly higher blood Mn concentrations than those who
were no longer welding (Bowler et. Al 2007). In both a study of 14 Chinese male welders and 9
smelters (Long et al. 2014) as well as in a study of gas transmission pipeline welders (Hassani et al.
2012), significantly elevated urine Mn was seen in occupationally exposed workers when compared
to controls.
In a group of 47 welding school students, sampled from a longitudinal cohort study, hair Mn
was associated with external air Mn concentrations (Reiss et. al 2016). In a cross-sectional study of
Mn-exposed dry cell battery workers, participants with high Mn exposure had significantly higher
hair Mn concentrations when compared to both low Mn-exposed and non-exposed workers (Bader
et. al 1999).
Despite their usefulness, these biomarkers have several imitations. Blood Mn is only
reflective of short-term Mn exposure due to the short half-life (t1/2 ) of Mn in blood (~ 2 hours – 40
days) (Mahoney and Small 1968; Zheng et al. 2000). Variability in urine Mn has limited its
usefulness as a biomarker. In the same study of dry cell battery workers conducted by Bader et. al
(1999), urine Mn was unable to distinguish between Mn-exposed workers and controls. Urine Mn
also has variability in its association with external air Mn concentrations (Laohaudomchok et al.
2011; Smith et. al 2007) possibly since only 1% of absorbed Mn is found in urine (Lauwerys and
Hoet 2001). Hair and nail Mn are also limited due to variation among individuals (Bader et. al 1999)
as well as potential external contamination.
Bone Mn (BnMn) has been suggested as a viable biomarker for cumulative Mn exposure due
to the metal’s extensive accumulation (40% of body burden) (Andersen et al. 1999) and relatively
long t1/2 (~8-9 years) in bone (O’Neal et al. 2014). BnMn is assessed using in vivo Neutron
Activation Analysis (IVNAA) technology that was initially developed by a team of researchers from
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McMaster University to assess Mn in the hand bones of Mn-exposed workers (Arnold et. al 2002).
Researchers from this team utilized the IVNAA system in a feasibility study to assess BnMn in a
group of 29 welders and 10 controls (Pejović-Milić et al. 2009). Welders BnMn was significantly
higher than that of controls, suggesting that BnMn is capable of distinguishing between exposure
groups. In the same study, Pejović-Milić et al. (2009) also assessed the relationship between BnMn
and a cumulative exposure index (CEI) reflecting participants’ lifetime occupational Mn exposure.
BnMn was significantly associated with participants’ lifetime occupational Mn exposure (ρ=0.436;
p-value = 0.0089), suggesting that BnMn is reflective of lifetime external air Mn exposure.
There is still limited data on the potential of BnMn as a biomarker of cumulative Mn
exposure. As a result, our research team has developed a transportable IVNAA system that can be
used to assess Mn in the hand bones of participants (Liu et al. 2013). The objective of this current
cross-sectional study is to determine whether BnMn measurements collected using the transportable
IVNAA system were correlated with other Mn exposure biomarkers and/or work history
information. To achieve this, BnMn in a group of Chinese workers was compared to exposure
estimates reflecting various exposure time periods: blood Mn (days), fingernail Mn (months), years
of employment in jobs with Mn exposure (years), ad a cumulative Mn exposure index (years). We
hypothesize that BnMn will be associated with exposure estimates reflecting long-term cumulative
exposure (i.e. years).
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3.2 Materials and Methods
Protocols and methods to establish a study population as well as collect and analyze Mn
biomarkers are the same as described in Chapter 2 methods, and therefore not repeated here. Work
history was collected using a questionnaire administered by study staff. Age and educational
attainment were also collected via this questionnaire. For current and past jobs, participants reported
their job titles, employer, and dates of employment Work history was used to create two cumulative
occupational Mn exposure indices (MnCEI) using methods adapted from prior research (Ramlow et
al. 1996, Fayerweather et al. 1997). One index included the entirety of each participant’s work
history (MnCEIT OT ). The second incorporated jobs held on or after the year 2000 (MnCEI 15 ); this
was an average of 16.1 (SD: 0.2) years prior to the study date. This date was chosen based on the t1/2
of BnMn (~8-9 years) with the assumption that ~16 years would represent approximately two t 1/2 for
BnMn, thus reflecting a period where a substantial amount of Mn could be expected to remain in
bone tissue.
To calculate the MnCEI, past and current jobs were first categorized into 20 occupational
groups based on Bureau of Labor Statistic’s Occupation Finder (Bureau of Labor Statistics. 2015)
(Table 8). These 20 occupational groups were divided into 3 exposure categories (high, medium, and
low) based on potential for occupational Mn exposure (Table 8). Determination of exposure category
for each occupational group was based on previously published data on air Mn concentrations
(Cowan et al. 2009a; Hedmer et al. 2014; Myers et al. 2003; Sierra et al. 1995; Westberg et al. 2001;
Zayed et al. 1996). Both the MnCEIT OT and MnCEI15 were calculated with the following equation,
where rank = the exposure groups (high = 3, medium = 2, low =1) for each job and Y = years
employed in the job.

39

The difference in calculation of the two CEIs is that for MnCEIT OT n=total number of jobs and for
MnCEI15 n=total number of jobs on or after the year 2000.
A variable for total years of occupational Mn exposure was also created for participants’
entire occupational history and for the previous 15 years. This is the sum of years employed in a
current or past job with the potential for Mn exposure. The potential of Mn exposure was based on
the same methods used for calculating the CEI. Jobs were considered to have Mn exposure if the
exposure rank was ≥2.

Table 8. Job Rank Classification for Study Population
Initial Occupational Categories
• Metal Ore Processing
(eg. smelting, welding, ore
extraction)
• Management at Ferroalloy
• Ferroalloy Transportation and
material moving
• Assemblers and Fabricators
• Ferroalloy Protective Service
• Installation Maintenance and
Repair
• Building and Grounds Cleaning
• Ferroalloy Water and
Wastewater Treatment
• Non-ferrous metal production
and processing
• Mining
• Molding
• Metal-refining furnace operators
and tenders
• Lime product manufacturing
• Ferroalloy misc. occupations

•
•

Historical Air Mn Example and Reference
Welders = 0.01 - 2.13 mg/m3 1
Ferroalloy Workers = 0.098–0.374 mg/m3 2

•

Ferroalloy Workers (not direct exposure) = 0.01–0.11 mg/m3

Occupational Mn Exposure
Direct

Rank
3

Potential

2

2

•
•
•

Mining = 0.21 mg/m3 3
Die-casting foundry = up to 0.14 mg/m3 4
Mn emitted from processing Mn-bearing material

1 Hedmer, Maria, Jan-Eric Karlsson, Ulla Andersson, et al.2014.Exposure to Respirable Dust and Manganese and Prevalence of Airways Symptoms, among Swedish

Mild Steel Welders in the Manufacturing Industry. International Archives of Occupational and Environmental Health 87(6): 623–634.
2 Cowan DM, Fan Q, Zou Y, Shi X, Chen J, Aschner M, et al. 2009. Manganese exposure among smelting workers: blood manganese –iron ratio as a novel tool for

manganese exposure assessment. Biomarkers 14:3–16; doi:10.1080/ 13547500902730672.
3 Myers JE, teWaterNaude J, Fourie M, Zogoe HBA, Naik I, Theodorou P, et al. 2003. Nervous System Effects of Occupational Manga nese Exposure on South African

Manganese Mineworkers. NeuroToxicology 24:649–656; doi:10.1016/S0161-813X(03)00035-4.
4 Westberg, Håkan B., Anders I. Seldén, and Tom Bellander. 2001. Exposure to Chemical Agents in Swedish Aluminum Foundries and Aluminum Remelting Plants?
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A Comprehensive Survey. Applied Occupational and Environmental Hygiene 16(1): 66–77.

Table 8. Continued
•
•
•
•
•
•
•
•
•
•
•
•

Advertisement and Marketing
(non-Mn related)
Misc. non-Mn related jobs
Transportation and Material
moving
Administrative support
Protective service
Installation, maintenance and
repair
Building and grounds cleaning
Sales
Industrial Designers
Automotive repair and
maintenance
Construction
Management

•
•
•

Workers from non-Mn-related factory = 0.00–0.04 mg/m3
Auto repair = 0.00045 mg/m3 . 5
Administrative Support = 0.001 mg/m3 . 5

No

1

Zayed, Joseph, Mourad Mikhail, Sylvain Loranger, Greg Kennedy, and Gilles L’Espérance.1996. Exposure of Taxi Drivers and Office Workers to Total and
Respirable Manganese in an Urban Environment. American Industrial Hygiene Association Journal 57(4): 376–380.
5
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Statistical analyses
All statistical analyses were completed using Stata 13.1 (College Station, Texas, USA). A pvalue < 0.05 was considered statistically significant. Study protocols were translated to Mandarin
then back-translated to English to check the accuracy of the data prior to use. Age and years of
education attained were collected from participants’ completed questionnaires. Tertiles of BnMn and
total years of occupational Mn exposure were created. BMn, fingernail Mn (FMn), and blood Mn
(BMn) concentrations were lognormally distributed; therefore, summary statistics are presented as
medians and interquartile ranges (IQRs). A natural log transformation of these variables was used in
analyses. A constant of 5.99 was added to all BnMn concentrations to ensure all values were positive
prior to the log transformation (Atkinson, AC. 1994). This method would affect measures of central
tendency for BnMn but its correlations or associations with other variables.
Mean and standard deviations (or median and IQRs) for demographic and Mn exposure
variables were reported for each tertile of BnMn as well as for the entire population. One-way
ANOVA was used to assess whether these variables were significantly different between BnMn
tertiles. Scatter plots with linear regression fit lines were created to show the relationship between
BnMn with other measurements of Mn exposure. Unadjusted and adjusted linear regression models
were created to determine the association between lnBnMn (continuous) and BnMn tertiles
(categorical) with each alternative measurement of Mn exposure. Covariates included in the adjusted
models were age (continuous) and education (continuous). FMn samples were analyzed using a
KXRF system pre- and post- cleaning. The difference between Mn concentrations in the samples
pre-and post-cleaning were calculated. A kernel density plot was created to visualize the distribution
of the difference. Several of the samples (N=7) had differences that were much larger than the other
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samples, suggesting possible external contamination. Sensitivity analyses were conducted for the
linear regressions without those 7 samples to see if results changed (Table 12).
3.3 Results
Table 9 shows summary measures for age, education, years in current occupation, years of
total occupational Mn exposure, years of occupational Mn exposure within the past 15 years,
MnCEIT OT , and MnCEI15 . Mean (SD) for age, education, total years of occupational Mn exposure,
and MnCEIT OT were not significantly different between BnMn tertiles. The number of years in the
participant’s current occupation were significantly different between BnMn tertiles (p = 0.006):
mean years in current occupation for the highest tertile of BnMn (11.4 years, SD=9.0) was more than
double that of the lowest tertile of BnMn (5.6 years, SD=2.9). MnYears 15 (p = 0.01) and MnCEI15 (p
= 0.002) significantly increased as BnMn increased.
Spearman correlation co-efficients for measures of Mn exposure are reported in Table 10.
BnMn was significantly correlated with FMn (p=<0.01), MnYears 15 (p=0.01), and MnCEI15
(p=<0.01) but was not associated with BMn (p=0.22), MnYearsT OT (p=0.31), and MnCEIT OT
( p=0.22).

All 4 measures of cumulative Mn exposure (MnYears 15 , MnYearsT OT , MnCEI15 , and

MnCEIT OT were significantly associated with each other.
Figure 10 shows unadjusted scatter plots and linear regressions for measures of Mn exposure
compared to ln(BnMn); further details about these unadjusted regression models as well as
regression models adjusted for age and education can be found in Table 11. Ln(BnMn) has a
positive, but not statistically significant, unadjusted association with ln(BMn) ( = 0.05; 95%
confidence interval (CI) = -0.03, 0.14) as well as MnCEIT OT ( = 4.73; 95% C.I. = -2.26, 11.72).
However, ln(BnMn) has a statistically significant, positive unadjusted association with ln(FMn) ( =
1.35; 95% CI = 0.70, 1.99) and MnCEI15 ( = 4.95; 95% CI = 1.54, 8.35). After adjusting for age and
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education these positive significant trends for ln(BnMn) with ln(FMn) ( = 1.38; 95% CI = 0.75,
2.00) or MnCEI15 ( = 5.33; 95% CI = 2.07, 8.59) persisted. Ln(BnMn) also had a statistically
significant association with MnYears15 ( = 1.73; 95% CI = 0.17, 3.30).
Figures 11 and 12 show FMn and BMn vs. Mn exposure measures, respectively. As both
MnYearsT OT and MnCEIT OT increase ln(FMn) decreases. However, once the Mn exposure variables
are limited within the past 15 years, ln(FMn) increases as both MnYears 15 and MnCEI15 increase.
Blood Mn makes little change as MnYearsT OT and MnCEIT OT increase. However, once the Mn
exposure variables are limited within the past 15 years, ln(BMn) also increases as both MnYears15
and MnCEI15 increase
The relationship between measures of Mn exposure with tertiles of BnMn are also displayed
in Table 11. The lowest tertile of BnMn is the reference group for these comparisons. After
adjustment for age and education, the highest tertile of BnMn was significantly associated with
higher ln(FMn) ( = 2.74; 95% CI= 1.51, 3.99) and MnCEI15 ( = 12.60; 95% CI = 6,38, 18.81).
MnYears15 was associated with both the middle ( = 4.10; 95% CI = 1.14, 7.05) and highest ( =
4.84; 95% CI = 1.92, 7.78) tertile of BnMn.
Results from sensitivity analyses (Table 12) still indicated statistically significant
associations between BnMn and several measures of cumulative Mn exposure (MnYears 15 : β=2.09;
95% Confidence Interval =0.09, 4.09); MnCEI15: β=6.90; 95% Confidence Interval = 2.83, 10.96). In
the sensitivity analyses, BnMn is also significantly associated with MnCEIT OT (β=7.89; 95%
Confidence Interval = 0.04, 15.70).

Table 9. Population Characteristics by Tertiles of BnMn
Characteristic
BnMn Tertiles
Total Population
-5.0 to 0.7
0.7 to 5.1
5.5 to 43.0
-5.0 to 43.0
Range of BnMn (g/g)
N
20
20
20
60
a
Age (years)
46.3 (8.3)
48.2 (8.4)
47.8 (7.3)
47.3 (7.9)
a
Education (years)
9.5 (4.6)
10.6 (3.3)
10.0 (3.7)
10.0 (3.9)
Years in Current Occupation a, c
5.6 (2.9)
9.9 (5.9)
11.4 (9.0)
9.0 (6.8)
a
Mn Years TO T
10.8 (9.3)
16.4 (10.7)
13.9 (8.3)
13.7 (9.6)
a,
c
Mn Years 15
6.2 (4.8)
9.8 (5.4)
10.8 (3.6)
8.9 (5.0)
MnCEITO T a
31.1 (17.6)
40.0 (23.2)
42.1 (24.2)
37.5 (22.0)
MnCEI15 a, c
19.5 (9.1)
24.2 (11.4)
31.2 (10.6)
25.0 (11.3)
b
13.2 (2.9)
14.3 (4.1)
14.4 (6.4)
14.1 (4.0)
Blood (g/L)
Fingernail (g/g) b, c
3.1 (13.7)
3.4 (29.7)
64.7 (286.32)
6.1 (39.8)
b,
c
-0.76 (2.6)
2.6 (2.5)
18.5 (21.1)
2.6 (7.2)
Bone (g/g)
Mn= Manganese; BnMn = Bone Manganese; MnYears = Years of Occupational Mn Exposure; MnCEI = Manganese Cumulative Exposure
Index; TOT = Lifetime occupational history; 15 = Occupational History since 2000.
a Mean (Standard Deviation)
b Median (Interquartile Range)
c = ANOVA p≤ 0.05 for differences across BnMn tertiles
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Table 10. Spearman’s ρ (p-value) for Correlations between Manganese Exposure Measurements, N=60.
MnYearsT OT
MnYears15
MnCEIT OT
Variable
BMn (g/L)
FMn (g/g)
BnMn (g/g)
BMn (g/L)
FMn (g/g)
0.25 (0.06)
a
0.16
(0.22)
0.44
(<0.01)
BnMn (g/g)
MnYearsT OT
0.06 (0.62)
-0.08 (0.53)
0.13 (0.31)
a
a
a
MnYears15
0.28 (0.03)
0.23 (0.07)
0.32 (0.01)
0.77 (<0.01)
MnCEIT OT
-0.008 (0.05) a
-0.10 (0.45)
0.16 (0.22)
0.85 (<0.01) a
0.59 (<0.01) a
a
a
a
a
MnCEI15
0.22 (0.09)
-0.43 (<0.01)
0.43 (<0.01)
0.58 (<0.01)
0.81 (<0.01)
0.66 (<0.01) a
Mn= Manganese; BMn = Blood Mn; FMn = Fingernail Mn; BnMn = Bone Manganese; MnYears = Years of Occupational Mn Exposure;
MnCEI = Manganese Cumulative Exposure Index; TOT = Lifetime occupational history; 15 = Occupational History since 2000.
a

= p≤ 0.05
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Figure 10. Scatterplots and Unadjusted Regression Lines of Natural Log BnMn vs. A: ln(BMn); B: ln(FMn); C: MnYearsTOT; D:
MnYears15; D: MnCEITOT; D: MnCEI15 (n=60)
Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn; MnYears = Years of Occupational
Mn Exposure; MnCEI = Manganese Cumulative Exposure Index; TOT = Lifetime occupational history; 15 = Occupational History
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since 2000.

Figure 11. Scatterplots and Unadjusted Regression Lines of Natural Log FMn vs. A: MnYearsTOT; B: MnYears15; C: MnCEITOT;
D: MnCEI15 (n=60)
Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn; MnYears = Years of Occupational Mn
Exposure; MnCEI = Manganese Cumulative Exposure Index; TOT = Lifetime occupational history; 15 = Occupational History since 2000.
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Figure 12. Scatterplots and Unadjusted Regression Lines of Natural Log FMn vs. A: MnYearsTOT; B: MnYears15; C: MnCEITOT;
D: MnCEI15 (n=59)
Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn; MnYears = Years of Occupational Mn
Exposure; MnCEI = Manganese Cumulative Exposure Index; TOT = Lifetime occupational history; 15 = Occupational History since 2000.
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Table 11. β (95% Confidence Interval) from Regression Models Comparing each Mn Exposure Measure to BnMn (N=60)
BnMn Tertiles a
Mn Exposure Measure/Model
ln(BnMn)
Tertile 2
Tertile 3
lnBMn
0.05 (-0.03, 0.14)
Unadjusted
0.02 (-0.15, 0.19)
0.14 (-0.04, 0.31)
b
Adjusted
0.05 (-0.12, 0.22)
0.15 (-0.02, 0.32)
0.06 (-0.03, 0.14)
lnFMn
1.35 (0.70, 1.99) c
Unadjusted
0.88 (-0.41, 2.16)
2.65 (1.36, 3.93) c
Adjustedb
1.08 (-0.17, 2.33)
2.74 (1.51, 3.99) c
1.38 (0.75, 2.00) c
MnCEIT OT
Unadjusted
8.27 (-5.58, 22.12)
10.93 (-2.92, 24.78) 4.73 (-2.26, 11.72)
b
Adjusted
6.35 (-6.80, 19.50)
9.38 (-3.67, 22.42)
3.42 (-3.19, 10.03)
MnCEI15 (years)
Unadjusted
4.67 (-1.91, 11.24)
11.73 (5.16, 18.31) c
4.95 (1.54, 8.35) c
b
c
Adjusted
6.19 (-0.08, 12.45)
12.60 (6.38, 18.81)
5.33 (2.07, 8.59) c
MnYearsT OT
Unadjusted
5.59 (-0.41, 11.60)
3.12 (-2.89, 9.12)
0.75 (-2.34, 3.85)
b
Adjusted
4.82 (-1.08, 10.73)
2.53 (-3.33, 8.39)
0.26 (-2.75, 3.27)
MnYears15
Unadjusted
3.65 (0.71, 6.60) c
4.59 (1.64, 7.54) c
1.63 (0.07, 3.18) c
Adjustedb
4.10 (1.14, 7.05) c
4.84 (1.92, 7.78) c
1.73 (0.17, 3.30) c
Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn; MnYears = Years of Occupational Mn Exposure;
MnCEI = Manganese Cumulative Exposure Index; TOT = Lifetime occupational history; 15 = Occupational History since 2000.
a
Tertile 1 (referent) includes BnMn values from -5.0 to 0.7; tertile 2 includes 0.7 to 5.1; tertile 3 includes 5.5 to 43.0
b
Adjusted for age(continuous) and education (continuous)
c
= p≤ 0.05
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Table 12. β (95% Confidence Interval) from Regression Models Comparing each Mn Exposure Measure to BnMn (N=53) (Sensitivity
Analysis)
BnMn Tertilesb
Mn Exposure Measure
ln(BnMn) Continuous
Tertile 2
Tertile 3
lnBMn
-0.03 (-0.12, 0.07)
Unadjusted
0.01 (-0.15, 0.17)
0.06 (-0.11, 0.23)
c
Adjusted
0.05 (-0.11, 0.20)
0.08 (-0.09, 0.25)
-0.02 (-0.11, 0.08)
lnFMn
0.78 (0.01, 1.54) d
Unadjusted
0.74 (-0.51, 2.00)
1.81 (0.44, 3.17) d
Adjustedc
1.03 (-0.18, 2.24)
2.03 (0.73, 3.32) d
0.88 (0.12, 1.61) d
MnCEIT OT
Unadjusted
8.71 (-5.76, 23.19)
15.95 (0.21, 31.70) d
9.23 (0.67, 17.8) d
c
d
Adjusted
5.21 (-8.16, 18.59) 14.91 (-0.59, 29.24)
7.89 (0.04, 15.7) d
MnCEI15 (years)
Unadjusted
4.31 (-2.48, 11.09)
13.17 (5.79, 20.56) d
6.33 (2.8, 10.5) d
Adjustedc
5.81 (-0.88, 12.51)
14.24 (7.06, 21.41) d
6.90 (2.83, 10.96) d
MnYearsT OT
Unadjusted
5.93 (-0.45, 12.30)
4.38 (-2.55, 11.31)
1.98 (-1.91, 5.85)
c
Adjusted
4.46 (-1.69, 10.61)
3.84 (-2.75, 10.43)
1.35 (-2.32, 5.02)
MnYears15
Unadjusted
3.64 (0.49, 6.79) d
4.86 (1.44, 8.29) d
1.96 (-0.003, 3.92)
c
d
Adjusted
4.10 (0.88, 7.32)
5.17 (1.72, 8.62) d
2.09 (0.09, 4.09) d
Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn; MnYears = Years of Occupational Mn
Exposure; MnCEI = Manganese Cumulative Exposure Index; TOT = Lifetime occupational history; 15 = Occupational History since 2000.
a N = XX excluded from analyses due to potential contamination of FMn biomarker (sensitivity analyses)
b Tertile 1 (referent) includes BnMn values from -5.0 to 0.7; tertile 2 includes 0.7 to 5.1; tertile 3 includes 5.5 to 43.0
c Adjusted for age(continuous) and education (continuous)
d = p≤ 0.05
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3.4 Discussion
We hypothesized that BnMn would be associated with MnCEI and MnYears, as these are
measures of long-term exposure, but not necessarily BMn or FMn. BnMn was significantly
associated with FMn but not BMn suggesting that BnMn is associated with at least months of Mn
exposure. The relationship between BnMn and a lifetime MnCEI calculated was previously assessed
for 30 welders and 10 controls (Pejović-Milić et al. 2009). They discovered that BnMn was
significantly associated with the MnCEI (ρ= 0.436; p=0.0089) demonstrating the utility of the
biomarker for cumulative exposure (Pejović-Milić et al. 2009). In our study, BnMn was not
significantly associated with lifetime Mn exposure variables (MnYears T OT , MnCEIT OT ). However,
when exposure history was limited to the previous 15 years, there was a significant relationship seen
between BnMn and cumulative exposure variables (MnYears 15 , MnCEI15 ), which persisted after
adjustment for age and education. These results suggest that BnMn is associated with exposure over
the past 15 years, but not necessarily over the worker’s full occupational career. Given the recently
reported BnMn t1/2 8.5 years (O’Neal et al. 2014), this suggests BnMn concentrations may reflect a
period of approximately 2 t1/2 s.
In contrast to other publications (Bouchard et al. 2008; Bowler et al. 2007; Lucchini et al.
1999)), we were unable to use current air Mn data to create a Mn CEI. However, we observed that
many participants from the ferroalloy factory primarily worked with wetted down ore. Therefore,
inhalation may not be the primary route of Mn exposure for many of the study participants. Thus, if
air measurements had been available, they may not have been fully reflective of the total worker Mn
exposure. Instead of using air concentrations, we adapted existing methods to rank exposure by job
title to approximate Mn exposure for our MnCEI (Ramlow et al. 1996, Fayerweather et al. 1997).
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There are several potential sources of bias for this method including exposure
misclassification and recall bias. Participants were required to recall employment history that for
some spanned decades. This could have affected the cumulative exposure variables due recall bias.
Additionally, exposure ranks were assigned based on the job titles thus misclassification could occur
due to jobs being incorrectly ranked due to a variation in expected exposures from the job title versus
the worker’s actual exposure.
Another limitation of this study was its small population size which could have resulted in
limited study power. However, as individuals with high Mn exposure were recruited we were still
able to observe statistically significant results with fewer study participants
It is also possible that our FMn estimates may have been biased by surface contamination.
Fingernails, instead of the more frequently used toenails, were used due to a concern that toenails
may have a greater risk of external contamination than fingernails. However, due to the work
practices of our study population, fingernails were suggested as a better biomarker to limit potential
external contamination. However, there is still a possibility of external contamination of fingernails,
particularly as we learned that some study participants lacked the proper personal protective
equipment, including gloves. To reduce the possibility of bias due to external contamination,
participants were asked to thoroughly wash their hands before fingernail samples were collected and
samples underwent two rounds of cleaning. We additionally conducted post-hoc sensitivity analyses
which suggested that our results were not due to external contamination.
Study protocols were originally developed in English and then translated into Mandarin for
this population. Questionnaire responses were provided in Mandarin then translated into English for
analyses. This could introduce some bias into the study due to translation errors or cultural
misunderstandings. To limit the language barrier in this study, native Mandarin speakers were used
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to administer the study protocol as well as translate the data back to English. Additionally, several
study staff members are fluent in both English and Mandarin
The IVNAA system did not perform as well as expected due to the impaired performance of
the HPGe detector system whose frequency was changed from 60 Hz in the US to 50 Hz in China
thus downgrading detector efficiency in detecting BnMn. Despite this, results from this study were
still able to demonstrate the potential utility of transportable IVNAA systems to non-invasively
assess BnMn in an occupational population and provide additional evidence that BnMn may be
associated with cumulative Mn exposure. Using, two different time periods for the CEI was a major
strength of this paper. This allowed us to establish a potential time-frame to which BnMn can
represent cumulative Mn exposure (previous 15-16 years). Future work should evaluate the
association of BnMn concentrations with impaired neurological health in Mn-exposed workers.
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CHAPTER 4. THE ASSOCIATION BETWEEN BONE, FINGERNAIL,
AND BLOOD MANGANESE WITH COGNITIVE AND OLFACTORY
FUNCTION

Abstract
Objective: Manganese (Mn) toxicity has been associated with cognitive dysfunction. An unresolved
question is the extent to which cognitive effects are due to cumulative Mn exposure. The goal of this
cross-sectional study is to assess bone Mn (BnMn)’s usefulness as a reliable indicator of decreased
cognitive function due to cumulative occupational exposure.
Approach: A transportable in vivo Neutron Activation Analysis (IVNAA) system was designed and
utilized to assess the BnMn of a group of Chinese workers (n=60). Blood (BMn) and fingernail Mn
(FMn) were also measured using inductively coupled plasma mass spectrometry (ICP-MS).
Information on potential covariates (age, education, current factory of employment) was collected
from participants using a questionnaire administered by a trained research assistant. A battery of
tests was administered to assess participants’ cognitive (Animal Naming, Fruit Naming, World
Health Organization/University of California-Los Angeles Audio Verbal Learning Test) and
olfactory (University of Pennsylvania Smell Identification Test) function. Spearman correlations as
well as multivariable regression models, adjusted for covariates, were used to assess the relationship
between Mn biomarkers (BnMn, FMn, and BMn) and test scores.
Main Results: After adjusting for age, education and current factory of employment in linear
regression models, BnMn was significantly associated with decreasing AVLT Avg. scores [ (95%
CI) = -0.6 (-1.2, -0.09)] along with decreasing Animal Naming scores [ (95% CI) = -1.5 (-3.0, 0.7)]. FMn was also significantly associated with decreases in AVLT Avg. scores [ (95% CI) = -0.4
(-0.7, -0.03))] as well as decreases in AVLT Difference Scores [ (95% CI) = -0.4 (-0.7, -0.02)].
BMn was not significantly associated with any test scores. Out of the three Mn biomarkers, BnMn
was associated with the greatest number of outcomes; BnMn predicted decreasing function in 5 out
of 9 scores.
Significance: These results suggest that BnMn, to a greater extent than FMn or BMn, is associated
with impaired cognitive function.
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4.1 Introduction
Manganese (Mn) is an essential element that is used in many cellular processes such as the
metabolism of lipids, proteins, and carbohydrates (Andreini et al. 2008). Jobs at risk for occupational
Mn exposure include mining, welding, smelting, ore-processing, ferroalloy steel production, dry-cell
battery manufacturing, and pesticide manufacturing (Ferraz et al. 1988; Chia et al. 1993; Bader et al.
1999; Lucchini et al. 1999; Myers et al. 2003; Bowler et al. 2006; Bowler et al. 2007; Cowan et al.
2009a; Cowan et al. 2009b).
Overexposure to the metal can result in cognitive neurological deficits such as decreased
audio-verbal short-term memory, verbal learning, visuomotor and visuospatial information
processing, and intellectual impairment and loss (Roels et al., 1987; Hua and Huang, 1991; Roels et
al., 1992; Bowler et al., 2003; Sadek et al., 2003; Bowler et al., 2006). Workers exposed to Mn also
experienced decreases in executive function, sustaining concentration, cognitive flexibility, and
working memory (Bowler et al. 2007; Bowler and Lezak, 2015). In addition to cognitive decline,
occupational Mn exposure can also result in decreased olfactory function (Antunes et al., 2007). In
extreme cases of exposure, Manganism can occur. Manganism is a disease similar but distinct from
idiopathic Parkinson’s disease due to differences in pathology (Calne et al., 1994).
To detect neurological symptoms of Mn exposure before irreversible damage is done, an
adequate biomarker of cumulative exposure is necessary. Biomarkers such as blood, urine, and
toenail have previously been used to assess the relationship between neuropsychological deficits and
occupational Mn exposure (Roels et al., 1987; Roels et al. 1992; Chia et al. 1993; Lucchini et al.
1995; Myers et al. 2003; Bowler et al. 2007; Cowan et al. 2009a; Hassani et al. 2016). However, due
to issues such as a short half-life (t1/2 ) of manganese, variability, and external contamination, these
biomarkers have been inconsistent in reflecting cognitive neuropsychological symptoms due to
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increased Mn body burden and cumulative exposure (Smith et al. 2007; Zoni et al. 2007;
Laohaudomchok et al. 2011; Zheng et al. 2011; O’Neal and Zheng 2015; Reiss et al. 2016).
Bone Mn has been suggested as a reliable biomarker of Mn body burden as 40% of Mn in the
body is stored in bone (Andersen et al. 1999; Arnold et al. 2002). Additionally, Mn has a relatively
long t1/2 in bone (~8-9 years) which would allow for information to be obtained on past exposures
and adverse health effects due to cumulative exposure (Arnold et al. 2002; O’Neal et al. 2014). Bone
Mn also helps to limit post-collection sample contamination as it is an in-vivo diagnostic method
(Arnold et al. 2002; Pejović-Milić et al. 2009). Currently, there are no biomarkers that adequately
reflect Mn doses in the brain (Apostoli et al. 2000). However, BnMn has been suggested to be a
reliable indicator of Mn concentrations in the brain as it has been correlated with Mn levels in the
striatum, hippocampus and cerebral spinal fluid (O’Neal et al. 2014). Results from the previous
chapter also suggest BnMn as a useful biomarker of cumulative exposures as BnMn was
significantly associated with Mn exposure within the past 15 years.
The goal of this cross-sectional study was to assess the association of BnMn and other Mn
biomarkers with neuropsychological deficits. The association of blood Mn (BMn) (reflecting several
days of exposure), fingernail Mn (FMn) (reflecting several months of exposure), and BnMn
(reflecting several years of exposure) with neuropsychological tests of verbal fluency, verbal
learning, and olfactory function were assessed to determine whether these biomarkers of Mn
exposure are better associated with reduced cognitive and olfactory function.
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4.2 Materials and Methods
Protocols and methods to establish a study population as well as collect and analyze Mn
biomarkers are the same as described in Chapter 2 methods, and therefore not repeated here. A group
of trained research assistants conducted individual neuropsychological assessments on participants
that included the animal and fruit naming tests of semantic verbal fluency, the World Health
Organization/University of California Los Angeles Auditory Verbal Learning Test (WHO/UCLA
AVLT), and the University of Pennsylvania Smell Identification Test – Traditional Chinese version
(UPSIT-TC).

Participants were asked to name as many 1) animal, and then 2) fruits that they

possibly could in 1 minute (Tombaugh et al. 1999; Bowler and Lezak, 2015). The WHO/UCLA
AVLT is a test of verbal learning and retention (Bowler et al. 2017; Maj et al. 1993). Participants
were given 15 common words and asked to repeat the list of words during five acquisition (learning)
trials (Bowler et al. 2017). After the five acquisition trials, a new interference list was given and
participants were yet again asked to repeat the list of words back to the trained research assistant
(trial 6) (Bowler et al. 2017). Finally, participants were asked to repeat as many words from the
original acquisition list in a post-interference recall trial (trial 7) (Bowler et al. 2017). The UPSITTC test consisted of four booklets each containing 10 odors (Jiang and Liang 2016). Participants
release each scent (N=40) using the tip of a pencil and are required to choose from 1 of 4 possible
scents given (Jiang and Liang 2016).
All statistical analyses were done using Stata 13.1 (College Station, Texas). A p-value < 0.05
was considered statistically significant. Demographic information was obtained from participants’
completed questionnaires including age, years of education completed, current drinking status, as
well as current smoking status. Tertiles of BnMn concentrations were also created. Natural log
transformations were performed on BMn (lnBMn), FMn (lnFMn) and BnMn (lnBnMn)
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concentrations before further analyses due to their lognormal distributions. A constant of 5.99 was
added to all BnMn concentrations so that all values were positive prior to the log transformation
(Atkinson, AC. 1994).
Animal and fruit naming scores were reported as the number of correct words a participant
gave. The difference in score between trial 5 and trial 1 (AVLT Dif.), as well as the average score
for the first five trials (AVLT Avg.) were created for the WHO/UCLA AVLT to show the number of
words learned across the five acquisition trials, as has been done previously (Bowler et al. 2017).
The number of correct words and number of incorrect words (intrusions) from the interference list
(trial 6) and recall list (trial 7) were also reported. Decreasing number of correct words and
increasing intrusions suggest worsening performance.
Mean and standard deviations (SDs) for cognitive and olfactory tests were reported for each
tertile of BnMn as well as for the entire population. A linear regression p-trend was used to assess
any statistical difference between BnMn tertiles for each variable. As the Mn biomarker
concentrations were lognormally distributed, these were summarized using medians and interquartile
ranges (IQR).
Unadjusted scatter plots with linear regression fit lines were created to show a visual
representation of the relationship between all 3 naturally log transformed biomarkers and
WHO/UCLA AVLT average scores and UPSIT scores. Spearman correlations were performed to
assess the association between potential covariates (age, education, factory of employment, length of
time in current position, current smoking status, current drinking status), Mn biomarkers (BnMn,
FMn, BMn) and test scores (Animal Naming, Fruit Naming, AVLT Avg. AVLT Dif., AVLT Trial 6,
AVLT Trial 6 Intrusions, AVLT Trial 7, AVLT Trial 7 Intrusions, UPSIT). Unadjusted and adjusted
regression models were created to assess how well naturally log transformed BnMn (continuous) and
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tertiles of naturally log transformed BnMn (categorical) predict the cognitive and olfactory test
scores. Beta-coefficients () and 95% Confidence Intervals (C.I.s) were reported. Covariates
included in the adjusted models were age (continuous), education (continuous), and current factory
of employment (dichotomous). Olfactory models were also adjusted for current smoking status
(dichotomous). These covariates were based on spearman correlations, model coefficients of
determination, and previous literature (Bowler et al. 2007). Sensitivity analyses were conducted for
the regression models without the 7 samples mentioned in chapter 3, to see if results changed (Tables
18 & 19).
4.3 Results
Population characteristics are reported in Table 13. Mean (SD) age and years of education
were 47.4 (7.9) and 10.0 (3.9) years respectively for the entire population. On average, participants
have been in their current position for 9.0 years (SD = 6.8). Years in current occupation was
significantly different between the BnMn tertiles (p=0.05). More than half of the total population
reported that they were current drinkers (73.3%) and current smokers (76.7%).
Summary statistics for the cognitive and olfactory tests as well as the biomarkers are reported
in Table 14. Both the AVLT 5-trial average scores (p=0.02) and olfactory scores (p=-0.05) were
significantly different across BnMn tertiles, with decreasing scores suggesting decreasing function as
BnMn increases. Both FMn (p=<0.01) and BnMn (P<0.01) are also significantly different across
BnMn tertiles with increasing concentrations as BnMn tertiles increase.
Scatter plots with unadjusted linear fit lines were created for BnMn, FMn, and BMn vs.
AVLT average scores (Figure 13) and olfactory scores (Figure 14). There was a significant decrease
in AVLT average scores [ (95% CI) = -0.9 (01.5, -0.2)] and olfactory scores [ (95% CI) = -1.7 (3.7, -0.03)] as BnMn increased. AVLT average scores [ (95% CI) = -0.5 (-0.7, -0.3)] and olfactory

61
scores [ (95% CI) = -1.1 (-1.7, -0.05)] also significantly decreased with increasing FnMn. There
was a significant decrease in AVLT average scores [ (95% CI) = -2.8 (-4.7, -0.9)] with increasing
BMn but not with olfactory scores [ (95% CI) = -5.2 (-10.5, 0.2)].
Spearman correlations between Mn biomarkers, test scores, and potential covariates are
reported in table 15. Current years in occupation, current factory of employment, age, and education
were all significantly associated with either a Mn biomarker or test score. After a Bonferroni
correction, the association between current factory and ln(FMn) (ρ=0.82, p = <0.01), education and
Animal Naming (ρ=0.46, p = <0.01), and ln(FMn) and AVLT Avg. (ρ=0.53, p = <0.01) remained
significant.
Adjusted regression models, assessing the relationship between the Mn biomarkers and test
scores, are reported in Tables 16 and 17. Increasing ln(BMn) was significantly associated with
decreasing Animal Naming scores [ (95% CI) = -1.5 (-3.0, -0.7)] and decreasing AVLT Avg.
scores [ (95% CI) = -0.6 (-1.2, -0.09)]. There was a decrease in AVLT Avg. scores [ (95% CI) = 1.2 (-2.3, -0.04)] when comparing the highest tertile of BnMn to the lowest. Decreasing scores for
Trial 6 were associated with the middle tertile of BnMn [ (95% CI) = -1.3 (-2.4, -0.08)] Trial 6
Intrusions increased for both the middle tertile [ (95% CI) = 0.5 (0.04, 0.9)] and highest tertile of
BnMn [ (95% CI) = 0.5 (0.07, 1.0)] when compared to the lowest tertile of BnMn. Increasing
ln(FMn) was also associated with decreasing AVLT Avg. scores [ (95% CI) = -0.4 (-0.7, -0.03)] as
well as decreasing AVLT Dif. Scores [ (95% CI) = -0.4 (-0.7, -0.02)].

When compared to the

lowest tertile, the highest tertile of FMn was significantly associated with decreasing AVLT Avg.
scores [ (95% CI) = -2.1 (-3.2, -1.0)]. BMn was not significantly associated with any of the
cognitive or olfactory test scores.

After performing the sensitivity analyses, there was still a

significant association between increasing FMn and decreasing AVLT Avg. scores [ (95% CI) = -
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0.5 (-0.8, -0.1)]. The middle tertile of BnMn was still associated with decreasing AVLT Trial 6
scores [ (95% CI) = -1.2 (-2.5, -0.04)].
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Table 13. Population Characteristics by BnMn Tertile and Total Population.
Characteristic
Total
BnMn T1
BnMn T2
BnMn T1
N (%)
Total
60 (100)
20 (100)
20 (100)
20 (100)
Age (years)
29 - 43
17 (28.3)
7 (35.0)
4 (20.0)
6 (30.0)
44 - 52
28 (46.7)
10 (50.0)
10 (50.0)
8 (40.0)
>52
15 (25.0)
3 (15.0)
3 (15.0)
6 (30.0)
Education (years)
0-8
18 (30.0)
9 (45.0)
3 (15.0)
6 (30.0)
9 - 13
30 (50.0)
7 (35.0)
13 (65.0)
10 (50.0)
>13
12 (20.0)
4 (20.)
4 (20.0)
4 (20.0)
Years in Current Occupationa
0-5
19 (31.7)
11 (55.0)
5 (25.0)
3 (15.0)
6 – 10
25 (41.7)
8 (40.0)
7 (35.0)
10 (50.0)
11 – 15
10 (16.6)
1 (5.0)
5 (25.0)
4 (20.0)
>15
6 (10.0)
3 (15.0)
3 (15.0)
Current Smoker
No
14 (23.3)
5 (25.0)
5 (25.0)
4 (20.0)
Yes
46 (76.7)
15 (75.0)
15 (75.0)
16 (80.0)
Current Drinker
No
16 (26.7)
6 (30.0)
6 (30.0)
4 (20.0)
Yes
44 (73.3)
14 (70.0)
14 (70.0)
16 (80.0)
Bone Mn Tertiles (BnMn T): Tertile 1 = -5.0 – 0.7 g/g; Tertile 2 = 0.7 – 5.1g/g; Tertile 3 = 5.5 –
43.0 g/g
a = significantly different between tertiles at ≤0.05 level

Table 14. Mean (Standard Deviation) of Cognitive and Olfactory Tests and Median (IQR) of Mn Biomarkers by BnMn tertile.
BnMn Tertiles
Test
Total Population
Variable

Total

BnMn T1

Animal Naming a
15.8 (5.0)
16.5 (5.1)
Fruit Naming a
11.3 (3.2)
11.4 (3.2)
a,
c
AVLT Avg.
8.5 (2.2)
9.1 (2.2)
a
AVLT Dif.
4.5 (2.0)
4.8 (2.0)
AVLT Trial 6 a
4.6 (1.9)
5.4 (2.2)
a
AVLT Trial 6 Int.
0.5 (0.7)
0.2 (0.4)
a
AVLT Trial 7
8.8 (3.4)
9.5 (3.7)
AVLT Trial 7 Int. a
0.4 (0.7)
0.5 (0.8)
a
UPSIT
20.2 (5.8)
21.7 (7.1)
a
MnCEIT OT
37.5 (22.0)
31.1 (17.6)
MnCEI15 a, c
25.0 (11.3)
19.5 (9.1)
b
BMn
14.1 (4.0)
13.2 (2.9)
FMn b, c
6.1 (39.8)
3.1 (13.7)
b,
c
BnMn
2.6 (7.2)
-0.8 (2.6)
Overall N = 60 (UPSIT N=58)
Bone Mn Tertiles (BnMn T): Tertile 1 = -5.0 – 0.7 g/g; Tertile 2 = 0.7 – 5.1g/g;
Fingernail Mn (FMn)
Blood Mn (BMn)
AVLT Avg. = average words correct over trials 1 – 5
AVLT Dif. = difference in words correct between trials 5 and 1;
AVLT Trial 6/7 Int. = number of intrusions during trials 6 and trial 7
a = Unadjusted means (standard deviations)
b = Unadjusted median (interquartile range)
c = significantly different at ≤0.05 level

BnMn T2

BnMn T3

p-value

16.2 (4.7)
11.9 (3.6)
8.9 (1.6)
4.6 (2.1)
4.1 (1.4)
0.6 (0.7)
8.7 (2.4)
0.4 (0.6)
21.0 (4.7)
39.4 (23.2)
24.2 (11.4)
14.3 (4.0)
3.4 (29.7)
2.6 (2.5)

14.5 (5.1)
10.5 (2.8)
7.5 (2.4)
4.0 (2.0)
4.4 (1.9)
0.6 (0.9)
8.1 (3.8)
0.3 (0.8)
18.0 (5.2)
42.0 (24.2)
31.2 (10.5)
14.4 (6.4)
64.6 (286.3)
18.5 (21.1)

0.2
0.4
0.02
0.2
0.1
0.1
0.2
0.4
0.05
0.1
<0.01
0.1
<0.01
<0.01

Tertile 3 = 5.5 – 43.0 g/g
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Figure 13. Scatterplots and unadjusted regression lines of natural log transformed Mn Biomarkers vs. AVLT Avg. Scores
Bone Mn (BnMn); Fingernail Mn (FMn); Blood Mn (BMn); AVLT Avg. = average words correct over trials 1 – 5
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Figure 14. Scatterplots and unadjusted regression lines of natural log transformed Mn Biomarkers vs. UPSIT Scores
Bone Mn (BnMn); Fingernail Mn (FMn); Blood Mn (BMn)
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Table 15. Spearman’s ρ (p-value) for Correlations between Manganese Biomarkers, Covariates and Test Scores N=58
Years in Current
Occupation

Factory

Smoking

Drinking

Age

Education

LogBn

LogFn

LogMn

Animal Naming

Fruit Naming

--

--

--

--

--

--

--

--

--

--

--

Factory

0.13 (0.31)

--

--

--

--

--

--

--

--

--

--

Smoking

0.11 (0.39)

0.16 (0.23)

--

--

--

--

--

--

--

--

--

Drinking

-0.03 (0.81)

0.00 (1.00)

0.19 (0.15)

--

--

--

--

--

--

--

--

Age

-0.07 (-0.61)

-0.16 (0.24)

-0.24 (0.07)

-0.11 (0.39)

--

--

--

--

--

--

--

Education

-0.04 (0.77)

-0.25 (0.06)

0.04 (0.74)

0.07 (0.59)

-0.10 (0.47)

--

--

--

--

--

--

a

0.13 (0.31)

0.18 (0.17)

0.14 (0.28)

0.03 (0.83)

--

--

--

--

--

0.14 (0.28)

0.12 (0.35)

0.008 (0.95)

-0.31 (0.02)

a

0.44 (<0.01)

--

--

--

--

-0.11 (0.42)

-0.02 (0.85)

-0.04 (0.77)

-0.25 (0.05)

a

0.16 (0.23)

0.25 (0.06)

--

--

--

--

--

Years in Current Occupation

ln(BnMn)

a

0.39 (<0.01)

ln(FMn)

0.15 (0.27)

ln(BMn)

0.23 (0.08)

0.26 (0.05)

0.82 (<0.01) a ,b
0.28 (0.03)

a

a

Animal Naming

-0.13 (-0.33)

-0.07 (0.59)

0.02 (0.82)

-0.08 (0.53)

-0.23 (0.09)

0.46 (<0.01) a , b

-0.20 (0.14)

-0.22 (0.09)

-0.11 (0.40)

Fruit Naming

-0.10 (0.44)

0.22 (0.10)

-0.07 (0.60)

-0.09 (0.48)

-0.10 (0.44)

-0.003 (0.98)

-0.14 (0.29)

0.05 (0.71)

-0.04 (0.75)

0.07 (0.58)

0.16 (0.22)

-0.31 (0.02) a

0.43 (<0.01)

0.01 (0.93)

0.07 (0.59)

-0.44 (<0.01)

0.04 (0.76)

0.05 (0.68)

-0.09 (0.50)

0.24 (0.07)

-0.20 (0.13)

-0.30 (0.02)

-0. 01 (-0.92)

0.08 (0.56)

0.04 (0.79)

-0.24 (0.07)

0.14 (0.29)

0.12 (0.39)

0.01 (0.93)

0.18 (0.18)

-0.26 (0.05)

-0.16 (0.24)

-0.35 (<0.01)

-0.22 (0.09)

-0.13 (0.32)

0.06 (0.63)

-0.20 (0.14)

-0.15 (0.27)

-0.18 (0.17)

-0.10 (0.44)

-0.03 (0.80)

-0.14 (0.31)

0.43 (<0.01)

AVLT Avg.

-0.26 (0.05)

a

a

-0.40 (<0.01)

AVLT Dif.

0.02 (0.77)

-0.01 (0.91)

AVLT Trial 6

-0.23 (0.07)

-0.28 (0.03)

AVLT Trial 6 Int.

0.02 (0.86)

-0.005 (0.97)

AVLT Trial 7

-0.17 (0.20)

-0.26 (0.05)

AVLT Trial 7 Int.

-0.11 (0.40)

-0.17 (0.20)

UPSIT

0.11 (0.41)

-0.35 (<0.01)

a

a

a

a

a

0.31 (0.02)

0.27 (0.04)

a
a

a

a

-0.34 (<0.01)

a

-0.23 (0.09)

-0.27 (0.04)

-0.53 (<0.01)

a b

,

-0.20 (0.13)

a

-0.40 (<0.01)

a

a

a

-0.32 (0.01)

a

0.42 (<0.01)
a

0.32 (0.01)

a

-0.14 (0.30)

-0.20 (0.14)

0.28 (0.03)

0.08 (0.57)

-0.17 (0.21)

0.19 (0.15)

0.21 (0.12)

0.06 (0.67)

-0.14 (0.29)

-0.22 (0.10)

-0.23 (0.08)

0.20 (0.03)

a

0.18 (0.18)

-0.09 (0.48)

0.03 (0.80)

0.08 (0.57)

-0.18 (0.18)

0.18 (0.17)

0.07 (0.56)
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Table 15. Continued
AVLT Avg.

AVLT Dif.

AVLT Trial 6

AVLT Trial 6 Int.

AVLT Trial 7

AVLT Trial 7
Int.

AVLT Dif.

0.47 (<0.01)

a, b

--

--

--

--

--

AVLT Trial 6

0.54 (<0.01)

a, b

0.24 (0.06)

--

--

--

--

a

--

--

--

a, b

-0.22 (0.09)

--

--

-0.07 (0.62)

--

AVLT Trial 6 Int.
AVLT Trial 7
AVLT Trial 7 Int.
UPSIT

-0.06 (0.67)
0.78 (<0.01)

a, b

-0.01 (0.92)
0.47 <0.01)

a, b

-0.11 (0.42)
0.42 (<0.01)

-0.29 (0.02)
a

0.009 (0.94)
0.44 (<0.01)

0.47 (<0.01)

-0.03 (0.80)
a

0.39 <0.01)

a

0.35 (<0.01)
-0.11 (0.40)

a

0.43 (<0.01)

a

0.10 (0.44)

Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn; ln(BnMn) = Natural Log of Bone Mn
AVLT Avg. = average words correct over trials 1 – 5
AVLT Dif. = difference in words correct between trials 5 and 1;
AVLT Trial 6/7 Int. = number of intrusions during trials 6 and trial 7
a = sig at ≤0.05 level
b = significant with Bonferroni correction
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Table 16. . β (95% Confidence Interval) from Adjusted Linear Regression Models Comparing
each Mn Biomarker to Test Scores
Test
ln(BnMn)
ln(FMn)
ln(BMn)
Animal Naming

-1.5 (-3.0, -0.7) c

-0.8 (-1.7, 0.08)

0.009 (-4.7, 4.7)

-0.4 (-1.5, 0.7)

-0.3 (-1.0, 0.3)

-1.1 (-4.4, 2.3)

AVLT Avg. a

-0.6 (-1.2, -0.09) c

-0.4 (-0.7, -0.03) c

-1.2 (-2.9, 0.6)

AVLT Dif. a

-0.2 (-0.9, 0.3)

-0.4 (-0.7, -0.02) c

-0.7 (-2.6, 1.2)

AVLT Trial 6 a

-0.2 (-0.8, 0.4)

-0.07 (-0.4, 0.3)

-0.02 (-1.9, 1.9)

AVLT Trial 6 Int. a

0.1 (-0.1, 0.3)

0.07 (-0.08, 0.2)

0.08 (-0.6, 0.8)

AVLT Trial 7 a

-0.5 (-1.5, 0.6)

-0.4 (-1.1, 0.2)

-0.9 (-4.1, 2.3)

AVLT Trial 7 Int. a

-0.2 (-0.4, 0.05)

-0.04 (-0.2, 0.1)

0.09 (-0.6, 0.8)

UPSIT a, b

-1.4 (-3.1, 0.2)

-0.6 (-1.6, 0.4)

-1.2 (-6.5, 4.2)

Fruit Naming

a

a

Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn;
ln(BnMn) = Natural Log of Bone Mn
N=58 for olfactory test model; N=60 for other regression models
a Adjusted for age(continuous), education (continuous), and current factory of employment
(dichotomous)
b Adjusted for current smoking status (dichotomous)
c = p≤ 0.05

Table 17. β (95% Confidence Interval) from Adjusted Regression Models Comparing Mn Biomarker Tertiles to Test Scores
Test
BnMn T2
BnMn T3
FMn T2
FMn T3
BMn T2
BMn T3
Animal Naming

a

-0.9 (-3.8, 2.0)

-2.5 (-5.5, 0.5)

-0.3 (-4.1, 3.4)

-2.0 (-7.1, 3.1)

1.2 (-1.8, 4.2)

-1.0 (-4.0, 2.0)

Fruit Naming a

0.3 (-1.8, 2.4)

-1.4 (-3.6, 0.8)

-1.6 (-4.3, 1.0)

-2.7 (-6.3, 0.9)

1.8 (-0.2, 3.8)

-1.4 (-3.5, 0.6)

AVLT Avg. a

-0.1 (-1.2, 1.0)

AVLT Dif. a

-02 (-1.4, 1.0)

-0.8 (-2.0, 0.4)

0.4 (-1.1, 1.9)

-0.1 (-2.2, 1.9)

-0.5 (-1.8, 0.7) -0.5 (-1.8, 0.7)

-1.3 (-2.4, -0.08) c

-0.6 (-1.9, 0.6)

0.9 (-0.6, 2.5)

0.2 (-1.9, 2.3)

0.5 (-0.7, 1.7)

0.5 (0.04, 0.9) c

0.5 (0.07, .1.0) c

0.2 (-0.3, 0.8)

0.5 (-0.2, 1.3)

-0.2 (-0.6, 0.3) 0.1 (-0.4, 0.6)

AVLT Trial 6 a

AVLT Trial 6 Int. a

-1.2 (-2.3, -0.04) c -0.6 (-1.7, 0.5) -2.1 (-3.2, -1.0) c -0.1 (-1.3, 1.0) -1.0 (-2.1, 0.1)

-0.6 (-1.9, 0.6)
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Table 17. Continued
AVLT Trial 7 a

AVLT Trial 7 Int. a

UPSIT a, b

-0.7 (-2.7, 1.3)

-0.9 (-3.0, 1.2)

-1.9 (-4.5, 0.6)

-2.7 (-6.2, 0.8)

0.3 (-1.8, 2.4)

-0.9 (-3.0, 1.2)

-0.09 (-0.6,
0.4)

-0.1 (-0.6, 0.4)

0.4 (-0.1, 1.0)

0.04 (-0.7, 0.8)

-0.1 (-0.6, 0.3)

-0.09 (-0.6, 0.4)

-1.0 (-4.3, 2.3)

-3.1 (-6.5, 0.3)

2.0 (-2.1, 6.1)

-1.0 (-6.7, 4.6)

-0.3 (-3.8, 3.2)

0.02 (-3.4, 3.5)

N=58 for olfactory test model; N=60 for other regression models
Bone Mn Tertiles (BnMn T): Tertile 1 (referent) = -5.0 – 0.7 g/g; Tertile 2 = 0.7 – 5.1g/g; Tertile 3 = 5.5 – 43.0 g/g
Fingernail Mn Tertiles (FMn T): Tertile 1 (referent) = -1.9 – 0.8 g/g ; Tertile 2 = 0.8 – 3.3 g/g ; Tertile 3 = 3.4 – 6.8 g/g
Blood Mn Tertiles (BMn T): Tertile 1 (referent) = 2.1 – 2.5 g/L ; Tertile 2 = 2.5 = 2.7 g/L ; Tertile 3 = 2.7 – 3.7 g/L
a Adjusted for age(continuous), education (continuous), and current factory of employment (dichotomous)
b Adjusted for current smoking status (dichotomous)
c = p≤ 0.05
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Table 18. β (95% Confidence Interval) from Adjusted Linear Regression Models Comparing
each Mn Biomarker to Test Scores (Sensitivity Analysis)
Test
ln(BnMn)
ln(FMn)
ln(BMn)
Animal Naming

-0.9 (-2.6, 0.7)

-0.5 (-1.5, 0.5)

0.6 (-4.5, 5.8)

-0.2 (-1.5, 1.1)

-0.2 (-1.0 (0.6)

-1.0 (-5.0, 3.0)

AVLT Avg. a

-0.5 (-1.2, 0.08)

-0.5 (-0.8, -0.1) c

-1.3 (-3.3, 0.6)

AVLT Dif. a

-0.4 (-1.1, 0.4)

-0.4 (-0.9, 0.03)

-0.6 (-3.0, 1.7)

AVLT Trial 6 a

-0.1 (-0.9, 0.6)

-0.09 (-0.5, 0.3)

-0.8 (-3.0, 1.5)

AVLT Trial 6 Int. a

0.09 (-0.2, 0.4)

0.06 (-0.1, 0.2)

0.2 (-0.7, 1.0)

AVLT Trial 7 a

-0.4 (-1.5, 0.8)

-0.6 (-1.3, 0.04)

-1.4 (-5.0, 2.1)

-0.2 (-0.5, 0.05)

-0.02 (-0.2, 0.1)

0.4 (-0.4, 1.3)

-1.3 (-3.4, 0.7)

-0.3 (-1.6, 0.9)

2.5 (-3.7, 8.7)

Fruit Naming

a

a

AVLT Trial 7 Int. a
UPSIT a, b

Mn= Manganese; ln(BMn) = Natural log of Blood Mn; ln(FMn) = Natural Log of Fingernail Mn;
ln(BnMn) = Natural Log of Bone Mn
N=51 for olfactory test model; N=53 for other regression models
a Adjusted for age(continuous), education (continuous), and current factory of employment
(dichotomous)
b Adjusted for current smoking status (dichotomous)
c = p≤ 0.05

Table 19. β (95% Confidence Interval) from Adjusted Regression Models Comparing Mn Biomarker Tertiles to Test Scores
(Sensitivity Analysis)
Test
BnMn T2
BnMn T3
FMn T2
FMn T3
BMn T2
BMn T3
Animal Naming

-1.6 (-4.5, 1.2)

-1.4 (-4.5, 1.7)

-0.4 (-4.1, 3.2)

-1.0 (-6.1, 4.1)

0.7 (-2.4, 3.7)

-0.7 (-3.9, 2.4)

-0.1 (-2.3, 2.1)

-1.2 (-3.6, 1.2)

-1.7 (-4.4, 1.0)

-2.6 (-6.5, 1.2)

1.8 (-0.4, 4.0)

-1.4 (-3.7, 0.8)

AVLT Avg. a

-0.1 (-1.2, 0.9)

-0.9 (-2.0, 0.3)

-0.4 (-1.8, 0.9)

-1.5 (-3.4, 0.3)

-0.3 (-1.5, 0.8)

-1.0 (-2.2, 0.2)

AVLT Dif. a

-0.2 (-1.5, 1.1)

-0.9 (-2.3, 0.5)

0.4 (-1.2, 2.1)

-0.03 ( -2.3 2.3)

-0.5 (-1.8, 0.9)

-0.5 (-1.9, 0.9)

AVLT Trial 6 a

-1.2 (-2.5, -0.04) c

-0.3 (-1.6, 1.0)

0.9 (-0.6, 2.5)

0.4 (-1.8, 2.6)

0.7 (-0.6, 2.0)

-1.1 (-2.4, 0.2)

AVLT Trial 6 Int. a

0.4 (-0.009, 0.9)

0.5 (-0.02, 1.0)

0.2 (-0.4, 0.8)

0.4 (-0.4, 1.3)

-0.3 (-0.8, 0.2)

0.07 (-0.4, 0.6)

Fruit Naming

a

a
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Table 19. Continued
AVLT Trial 7 a

-0.6 (-2.6, 1.4)

-0.4 (-2.6, 1.7)

-2.0 (-4.4, 0.5)

-2.5 (-5.9, 1.0)

0.6 (-1.5, 2.7)

-0.7 (-2.9, 1.4)

AVLT Trial 7 Int. a

-0.09 (-0.6, 0.4)

-0.2 (-0.7, 0.3)

0.4 (-0.1, 1.0)

-0.1 (-0.9, 0.7)

-0.3 (-0.8, 0.2)

-0.05 (-0.6, 0.5)

UPSIT a, b

-1.1 (-4.5, 2.4)

-3.0 (-6.8, 0.7)

2.0 (-2.3, 6.2)

-0.9 (-7.1, 5.2)

0.1 (-3.7, 3.9)

1.7 (-2.0, 5.5)

N=51 for olfactory test model; N=53 for other regression models
Bone Mn Tertiles (BnMn T): Tertile 1 (referent) = -5.0 – 0.7 g/g; Tertile 2 = 0.7 – 5.1g/g; Tertile 3 = 5.5 – 43.0 g/g
Fingernail Mn Tertiles (FMn T): Tertile 1 (referent) = -1.9 – 0.8 g/g ; Tertile 2 = 0.8 – 3.3 g/g ; Tertile 3 = 3.4 – 6.8 g/g
Blood Mn Tertiles (BMn T): Tertile 1 (referent) = 2.1 – 2.5 g/L ; Tertile 2 = 2.5 = 2.7 g/L ; Tertile 3 = 2.7 – 3.7 g/L
a Adjusted for age(continuous), education (continuous), and current factory of employment (dichotomous)
b Adjusted for current smoking status (dichotomous)
c = p≤ 0.05
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4.4 Discussion
The purpose of this study was to assess the association of Mn biomarkers, particularly BnMn,
with cognitive and olfactory test scores. Based on the results, after adjusted for covariates, BnMn
was significantly associated with decreasing function in the AVLT Avg. scores, AVLT trial 6,
AVLT trial 6 intrusions, as well as animal naming scores. Additionally, after adjusting for
covariates, FMn was significantly associated with decreasing function in the AVLT Avg. scores and
AVLT Dif. Scores whereas BMn was not significantly with any outcomes. BnMn was also the
greater predictor of decreasing function when compared to FMn or BMn. BnMn was associated with
decreasing function in 5 out of 9 outcomes.
The association between Mn biomarkers and olfactory function has varied in the literature.
Urine Mn (UMn) has previously been associated with increasing olfactory function (Lucchini et al.
1997). Antunes et al. (2007) saw no significant correlation between BMn and UPSIT scores in a
group of bridge welders (ρ= 0.20; p=<0.20). Mn exposure has also been associated with decreases in
olfactory function in a group of bridge welders (Bowler et al. 2007; Bowler et al. 2011). In our
study, after adjusting for covariates, all 3 biomarkers had associations with decreasing olfactory
function. However, these associations were not significant.
Mn has also been shown to be associated with decreasing cognitive function. BMn and TMn
have previously been associated with decline in several cognitive tests that assess visual and spatial
working memory (Hassani et al. 2016). BnMn in rats has been associated with Mn concentrations in
both the hippocampus and striatum, two parts of the brain that play an important role in cognition
(O’Neal et al. 2014). In our study, BnMn was significantly associated with decreases in both AVLT
and Animal Naming tests, two well-established tests of verbal memory and fluency. Verbal memory
tests like the AVLT have been associated with hippocampal impairment (Vyhnalek et al. 2014)
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whereas verbal fluency tests like the Animal Naming test have been associated with decreased
striatal matter (Ellfolk et al. 2014). Our results suggest that BnMn may be reflective of decreasing
verbal memory and fluency and possibly decreased striatal and hippocampal function.
There are several limitations associated with this study. Firstly, the cross-sectional design of
the study limits our ability to draw any conclusions about temporality and causality. Secondly,
although this study controlled for age, education and exposure status through current factory of
employment, there may have been other potential covariates that could have explained the
relationship between Mn biomarkers and test scores. For example, FMn and BMn could have been
included as covariates in models with BnMn as they may have contributed to the variance seen in the
model. The use of fingernails in our study could also be a potential limitation. We took precautions
to limit the external contamination present on the fingernail samples, however our results could have
still been affected. We performed a sensitivity analysis (Tables 18 & 19) that excluded the samples
that are most-likely at risk for contamination. We still saw significant associations between FMn
and decreasing AVLT. Avg. scores [ (95% CI) = -0.5 (-0.8, -0.1)] as well as the middle tertile of
BnMn and decreasing AVLT Trial 6 scores [ (95% CI) = -1.2 (-2.5, -0.04)] suggesting that some of
the variance in the models could not be explained by potential contamination.
Use of the IVNAA system was a strength of this study. This technology, which is not
available to many others, allowed our team to assess BnMn in an occupational population. Using
well-established cognitive and olfactory tests was also a major strength of this study. These tests
have already been used in non-English speaking populations and can stand up to the cultural
differences. Having research assistants both fluent in English and Mandarin was also a strength as it
helped to limit any cultural miscommunication. Future work should assess the association between
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BnMn and motor function as Mn exposure has also been associated with decreases in motor function
and the development of the motor disease Manganism.
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CHAPTER 5. THE ASSOCIATION BETWEEN BONE, FINGERNAIL,
AND BLOOD MANGANESE WITH MOTOR FUNCTION: BONE
MANGANESE AS A RELIABLE INDICATOR OF DECREASED MOTOR
FUNCTION

Abstract
Objective: Manganese (Mn) is an essential element that is important for several bodily functions.
However, overexposure to the metal has been associated with decreased motor function. The goal of
this cross-sectional study is to assess the association of bone Mn (BnMn), a novel biomarker of longterm Mn exposure, with motor function.
Approach: To assess motor functions, participants completed the Purdue Pegboard test of manual
dexterity as well as the CATSYS computerized motor system. Spearman correlations and
multivariable regression models (linear and nonlinear) were used to assess the relationship between
Mn biomarkers (BnMn, FMn, and BMn) with the motor test scores.
Main Results: After adjusting for age, education, current factory of employment, and current
drinking status, increasing ln(BnMn) was associated with decreasing Rhythmic P/S fast (NonDominant Hand) (β = -0.019; 95% C.I. = -0.036, -0.002), decreasing Rhythmic F-Tap fast (NonDominant Hand) (β = -0.027; 95% C.I. = -0.045, -0.008), increasing Center frequency (Dominant
Hand) (β = 0.443; 95% C.I. = 0.029, 0.858), and increasing tremor intensity (β = 0.011; 95% C.I. =
0.0001, 0.022). Lowess curves and spline regressions suggest a non-linear relationship between
lnBnMn and several motor outcomes.
Significance: Our results suggest that for some motor outcomes, a non-linear model may best fit the
relationship between motor outcomes and BnMn.
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5.1 Introduction
Manganese (Mn) toxicity has been associated with neurotoxic effects including decreased
motor function. Occupational overexposure to the metal has resulted in decreased psychomotor
function (Lucchini et al. 1997), general motor function (Ma et al. 2017), and manual dexterity
(Cowan et al. 2009; Wells et al. 2017). Chronic manganese exposure has been associated with
increased reaction time, impaired finger-tapping and digit-span performance scores (Wennberg et al.
1991), as well as grooved pegboard scores (Wastensson et al. 2012).
In cases of high or chronic manganese exposure, the development of Manganism, a disease like
idiopathic Parkinson’s disease, can occur (Calne et al. 1994; Lucchini et al. 2009). Despite this
evidence, the relationship between chronic Mn exposure and motor dysfunction is still not quite
understood due to the lack of a biomarker for cumulative Mn exposure (Chen et al. 2016).
Bone manganese (BnMn) has previously been suggested as a viable biomarker of cumulative
Mn exposure due to ~40% of Mn’s body burden being found in bone as well as the relatively long
half-life of the metal in bone (8.6 years). (Arnold et al. 2002; O’Neal et al. 2014). BnMn was also
associated with Mn concentrations found in the brain suggesting that BnMn could be reflective of
Mn in target tissues of neurologic function (O’Neal et al. 2014). Our research team developed a
transportable in vivo Neutron Activation Analysis (IVNAA) system capable of assessing BnMn at
different field sites (Liu et al. 2013; Liu et al. 2014; Liu et al. 2017). This transportable IVNAA
system was used to assess BnMn in a group of 19 adult males (Wells et al. 2018). In this pilot study,
BnMn was significantly associated with decreased manual dexterity.
The goal of the study is to utilize the same transportable IVNAA technology in a larger
epidemiology study to assess BnMn as a reliable indicator of motor dysfunction due to cumulative
Mn exposure. In the study we assessed the association between Mn biomarkers representing various
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lengths of time (blood Mn (BMn) (days), fingernail Mn (FMn) (months), and BnMn (years)) and
tests of motor function (The CATSYS System and the Purdue Pegboard).
5.2 Materials and Methods
Protocols and methods to establish a study population as well as collect and analyze Mn
biomarkers are the same as described in Chapter 2 methods, and therefore not repeated here.
Participants completed the CATSYS battery and the Purdue Pegboard test with the aid of trained
research assistants. The CATSYS 2000 system (Snekkersten, Denmark) is a computerized test that
assesses tremor, postural stability, reaction time and coordination CATSYS testing procedures are
explained in depth elsewhere (DPD 2000; Ellingsen et al. 2015). The standard CATSYS battery was
used in this study. A tremor-sensitive stylus (Figure 15 item 5) was used to assess tremor in
participants’ hands. While sitting in a chair, participants held the stylus like a normal pen about a
hand-length in front of their waist. Participants were required to hold the stylus as still as possible,
without any support, for approximately 10 seconds. This was repeated for both the right and left
hand. Four tremor values were produced for each hand: tremor intensity, central frequency,
harmonic index, and tremor deviation.
Postural stability was assessed using a force plate (Figure 15 item 1) that records vertical
forces in 3 points to determine the position of the force center on the plate. Participants were asked
to stand on the plate without their shoes and stare ahead to a spot on the wall. Four balance tests,
each running for one minute, were performed: SWAY 1) eyes open on plate; SWAY 2) eyes closed
on plate; SWAY 3) eyes open on plate with ~ 1cm polystyrene foam placed on top of plate; and
SWAY 4) eyes closed with ~ 1cm polystyrene foam placed on top of plate. Scores from the normal
conditions (test 1) were reported in this study.
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Coordination and controlled movement was assessed using a recording drum (Figure 15 item
4) with a microphone inside that records hand movement. To ensure accurate testing, the drum was
placed on a computer mousepad a top a desk. Tests performed using this drum include the hand
pronation/supination

tests,

finger

tapping

tests,

and

max

frequency

tests.

For

the

protonation/supination (P/S) tests, participants were asked to hit the drum palm up and then palm
down in tune with the provided beep for 20 seconds. The first test was at a slow pace of ~ 1
hit/second (beep). The second test was at a faster pace where participants were asked to hit the drum
in time with the beep. These tests were repeated for both hands. For the finger-tapping (F-Tap) tests,
the methods were repeated using participants’ index finger. The outcomes produced for each hand
were Rhythmic P/S Slow, Rhythmic P/S Slow Standard Deviation, Rhythmic P/S Fast, Rhythmic
P/S Fast Standard Deviation, Rhythmic F-Tap Slow, Rhythmic F-Tap Slow Standard Deviation,
Rhythmic F-Tap Fast, and Rhythmic F-Tap Fast Standard Deviation
For the max frequency tests (Max Frequency P/S and May Frequency F-Tap) participants
were required to perform the movements for as long as they could in time with the metronome beep
as it increased in pace. Outcomes were produced for each hand. Reaction time was assessed using a
reaction handle (Figure 15 item 3). Participants used their thumb to press the black button on the
handle in response to a beep from the system. This test was repeated for both the right and left hand.
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Figure 15. CATSYS motor system (DPD 2000)
1: Force Plate; 2: Data Logger; Reaction Handle; 4: Recording Drum; 5: Tremor-sensitive Stylus

The Purdue Pegboard (Lafayette Instruments, Lafayette, IN, USA) test (Figure 16) is
a test of manual dexterity that has been described elsewhere previously (Cowan et al. 2009). The
pegboard procedure consists of 4 operations that focus on the coordination of 1) the right hand; 2)
the left hand; and 3) both hands. For the first test, participants must place as many pegs down the
right side of the board as they can in 30 seconds using just their right hand. This is repeated for the
second test using just their left hand down the left side of the board. For the third test, participants
use both hands to place as many pegs down both sides as they can in 30 seconds. For the fourth test,
participants are required to construct as many assemblies, made from pins, washers, and collars, as
they can in 1 minute. This test was repeated twice, and an average score was provided.
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Figure 16. Purdue Pegboard motor system (LIC 2009).
All statistical analyses were done using Stata 13.1 (College Station, Texas). Mean (standard
deviation) of test scores were reported for the entire population as well as by tertile of BnMn.
Several test scores were produced from the CATSYS and Purdue Pegboard tests and were evaluated
based on dominant (Dom) vs. non-dominant (NonDom) hand. A linear-regression p-trend was used
to assess any statistical difference in means for each outcome as BnMn tertile increased. A p-value <
0.05 was considered statistically significant.
Unadjusted Spearman correlations and multivariable linear regression models (adjusted for
age, education, current factory of employment, and current drinking status) were performed to assess
the association between the natural log transformed Mn biomarkers [ln(BMn), ln(FMn), and
ln(BnMn)] with the motor test scores. Locally weighted scatter plot smoothing (LOWESS) curves
were created to assess the possible non-linear relationship between the biomarkers and the test
scores. Based on these graphs, it was shown that for many of the test scores, the linear relationship
with Mn changed as the concentration increased. As a result, linear splines with two knots for each
Mn biomarker were created based on each LOWESS curve. This allowed for a piecewise estimation
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of the relationship between the Mn biomarkers and the test scores. Outliers for motor tests were
removed from each model based on the LOWESS curve. A data point was considered an outlier if it
skewed the curve for all 3 biomarkers. Removing these outliers did create a smoother LOWESS
curve. Spearman correlation coefficients (ρ) and p-values (p) were reported for the Spearman
correlations. Due to the number of outcomes, the chances of a significant p-value being solely due to
chance increases. Therefore, a more stringent p-value < 0.01 was considered statistically significant
for the Spearman correlations.

Beta-coefficients () and 95% Confidence Intervals (C.I.s) were

reported for the regression models. A p-value < 0.05 was considered statistically significant.
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5.3 Results
Mean (standard deviation) of motor tests scores are reported in Table 20. There was a
significant decrease in precision for the Rhythmic P/S test at the slow speed (NonDom) as BnMn
tertiles increase (p = 0.03). Tremor deviation significantly decreased as BnMn increased for both the
dominant (p=0.04) and non-dominant hands (p=0.04). The Spearman correlation co-efficient for the
associations between covariates, Mn biomarkers and motor test scores are reported in Table. 21. Age
was significantly associated with decreases in Max Frequency P/S (NonDom) (ρ = -0.33; p = 0.01),
Max Frequency F-Tap (Dom) (ρ = -0.39; p = <0.01), and Purdue Pegboard scores for both hands (ρ
= -0.38; p = <0.01). Age was also significantly associated with increased Sway Velocity for both
Sway test 3 (ρ = 0.33; p = 0.01) and Sway 4 (ρ = 0.32; p = 0.01). Education was associated with
decreasing precision in the Rhythmic P/S test slow (NonDom) (ρ = -0.38; p = <0.01) and increasing
Purdue Pegboard Assembly scores (ρ = 0.33; p = <0.01).
Current factory of employment was associated with decreasing Tremor Standard Deviation
(Dom) (ρ = -0.33; p = 0.01), decreasing Mean Sway (Test 1) (ρ = -0.39; p = <0.01), decreasing
Transversal Sway (Test 1) (ρ = -0.38; p = <0.01), and decreasing Purdue Pegboard Assembly scores
(ρ = -0.33; p = 0.01). Drinking status was associated with decreasing Max Frequency P/S (Dom) (ρ
= -0.37; p = <0.01), increasing Center Frequency (Dom) (ρ = 0.33; p = 0.01), and increasing Sagittal
Sway (Test 2) (ρ = 0.32; p = 0.01). BMn was associated with increasing Sway Velocity (Test 2) (ρ =
0.32; p = 0.01). FMn was associated with decreasing Max Frequency P/S (Dom) (ρ = -0.32; p =
0.01), decreasing Transversal Sway (Test 1) (ρ = -0.40; p = <0.01), and decreasing Sway Area (Test
1) (ρ = -0.35; p = <0.01). FMn was also significantly associated with current factory of employment
(ρ = 0.82; p = <0.01) and BnMn (ρ = 0.41; p = <0.01). BnMn was not significantly associated with
any of the motor test outcomes at the 0.01 level.
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An example of the lowess curves created for Mn biomarkers vs. motor tests is shown in
Figure 17 (FMn vs. Max Frequency Finger Tap NonDom). In this figure, the relationship between
Mn and the outcome appears to have a sigmoidal shape, not linear. Tables 22 – 24 provide the βcoefficients and 95% Confidence Intervals for the association between motor tests and Mn
biomarkers (continuous and splines). After adjusting for age, education, current factory of
employment, and current drinking status, increasing ln(BnMn) was associated with decreasing
Rhythmic P/S fast (NonDom) (β = -0.019; 95% C.I. = -0.036, -0.002), decreasing Rhythmic F-Tap
fast (NonDom) (β = -0.027; 95% C.I. = -0.045, -0.008), increasing Center frequency (Dom) (β =
0.443; 95% C.I. = 0.029, 0.858), and increasing tremor intensity (β = 0.011; 95% C.I. = 0.0001,
0.022).
When ln(BnMn) was divided into low, medium, and high concentrations, the relationship
between the biomarker and motor tests changed as Mn increased. For example, for the Rhythmic FTap slow SD test, the lowest (β = 0.057; 95% C.I. = 0.004, 0.109) and highest (β = 0.052; 95% C.I. =
0.014, 0.091) concentrations were associated with increases in the SD whereas the medium
concentrations were associated with decreasing (β = -0.069; 95% C.I. = -0.115, -0.023) SD. The
highest concentrations of ln(BnMn) was associated with decreasing scores for the Purdue Pegboard
test for both hands (β = -1.212; 95% C.I. = --2.350, -0.074).
Continuous ln(FMn) was associated with decreasing Max Frequency P/S (Dom) (β =
-0.380; 95% C.I. = -0.652, -0.109) and decreasing Max Frequency F-Tap (Dom) (β = -0.316; 95%
C.I. = -0.604, -0.028). The highest concentrations of lnFMn was associated with increasing sway for
several sway outcomes under the Sway 2 conditions. Continuous ln(BMn) was associated with
decreasing Rhythmic P/S slow (NonDom) (β = -0.092; 95% C.I. = -0.178, -0.005) , decreasing
Rhythmic P/S Fast (Dom) (β = -0.061; 95% C.I. = -0.118, -0.005), decreasing Rhythmic F-Tap slow
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(NonDom) (β = -0.103; 95% C.I. = -0.203, -0.004), increasing sway velocity (Sway 2) (β = 4.82;
95% C.I. = 1.00, 8.65), and increasing sway intensity (β = 2.07; 95% C.I. = 0.71, 3.43).

Table 20. Mean (Standard deviation) of motor tests by BnMn tertile
BnMn Tertiles
Motor Test

Total Population
Tertile 1

Tertile 2

Tertile 3

p-value

Reaction Time (Dom)

0.27 (0.08)

0.29 (0.13)

0.26 (0.04)

0.26 (0.05)

0.24

Reaction Time (NonDom)

0.26 (0.05)

0.26 (0.05)

0.25 (0.03)

0.26 (0.07)

0.98

Max Frequency P/S (Dom)

5.05 (1.41)

5.27 (1.49)

5.22 (1.34)

4.62 (1.38)

0.16

Max Frequency P/S (NonDom)

5.10 (1.18)

5.06 (1.24)

5.05 (1.20)

5.19 (1.17)

0.76

Max Frequency F-Tap (Dom)

6.17 (1.42)

6.27 (1.48)

6.26 (1.34)

5.96 (1.50)

0.51

Max Frequency F-Tap (NonDom)

5.72 (1.59)

5.35 (1.13)

5.66 (1.91)

6.21 (1.61)

0.10

Rhythmic Test P/S slow (Dom)

-0.10 (0.09)

-0.08 (0.11)

-0.11 (0.06)

-0.10 (0.09)

0.41

Rhythmic Test P/S slow SD (Dom)

0.07 (0.050

0.07 (0.05)

0.06 (0.04)

0.07 (0.05)

0.67

Rhythmic Test P/S slow (NonDom)

-0.10 (0.08)

-0.07 (0.09)

-0.11 (0.06)

-0.12 (0.08)

Rhythmic Test P/S slow SD (NonDom)

0.07 (0.05)

0.07 (0.06)

0.06 (0.04)

0.08 (0.06)

0.76

Rhythmic Test P/S fast (Dom)

-0.05 (0.05)

-0.06 (0.06)

-0.05 (0.05)

-0.06 (0.05)

0.98

Rhythmic Test P/S fast SD (Dom)

0.07 (0.05)

0.06 (0.04)

0.06 (0.05)

0.08 (0.05)

0.19

Rhythmic Test P/S fast (NonDom)

-0.06 (0.05)

-0.06 (0.05)

-0.03 (0.03)

-0.07 (0.06)

0.87

Rhythmic Test P/S fast SD (NonDom)

0.07 (0.04)

0.07 (0.04)

0.06 (0.04)

0.09 (0.05)

0.44

Rhythmic Test F-Tap slow (Dom)

-0.08 (0.09)

-0.05 (0.10)

-0.09 (0.08)

-0.10 (0.08)

0.07

Rhythmic Test F-Tap slow SD (Dom)

0.08 (0.06)

0.09 (0.07)

0.05 (0.01)

0.09 (0.06)

0.64

Rhythmic Test F-Tap slow (NonDom)

-0.07 (0.09)

-0.05 (0.08)

-0.08 (0.08)

-0.10 (0.10)

0.10

Rhythmic Test F-Tap slow SD (NonDom)

0.07 (0.05)

0.09 (0.06)

0.05 (0.01)

0.07 (0.04)

0.06

Rhythmic Test F-Tap fast (Dom)

-0.09 (0.05)

-0.10 (0.06)

-0.09 (0.05)

-0.09 (0.05)

0.72

Rhythmic Test F-Tap fast SD (Dom)

0.05 (0.03)

0.05 (0.03)

0.04 (0.03)

0.05 (0.04)

0.56

Rhythmic Test F-Tap fast (NonDom)

-0.09 (0.06)

-0.09 (0.07)

-0.07 (0.04)

-0.10 (0.06)

0.74

Rhythmic Test F-Tap fast SD (NonDom)

0.05 (0.03)

0.04 (0.03)

0.04 (0.03)

0.05 (0.03)

0.71

0.03

a
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Table 20. Continued
Tremor Intensity Dom (m/s 2 )

0.10 (0.03)

0.09 (0.02)

0.11 (0.04)

0.11 (0.02)

0.19

Center Frequency Dom (Hz)

7.60 (1.25)

7.06 (1.06)

7.96 (1.50)

7.79 (0.96)

0.06

Harmonic Index Dom

0.91 (0.04)

0.91 (0.04)

0.90 (0.05)

0.92 (0.03)

0.46

Tremor SD Dom

3.02 (0.77)

3.19 (0.57)

3.16 (0.91)

2.66 (0.72)

Tremor Intensity NonDom (m/s 2 )

0.10 (0.03)

0.10 (0.04)

0.10 (0.03)

0.11 (0.03)

0.76

Center Frequency NonDom (Hz)

8.07 (1.41)

8.17 (1.40)

8.32 (1.59)

7.67 (1.17)

0.29

Harmonic Index NonDom

0.89 (0.04)

0.88 (0.04)

0.88 (0.05)

0.90 (0.03)

0.20

Tremor SD NonDom

3.39 (0.71)

3.51 (0.52)

3.57 (0.66)

3.04 (0.85)

0.04

0.04

a

a
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Table 20. Continued
Sway 1: Mean Sway

4.55 (1.34)

4.92 (1.30)

4.11 (0.99)

4.63 (1.63)

0.47

Sway 1: Transversal Sway

2.19 (0.65)

2.29 (0.62)

2.15 (0.71)

2.11 (0.64)

0.39

Sway 1: Sagittal Sway

3.52 (1.23)

3.88 (1.23)

3.04 (0.75)

3.65 (1.52)

0.53

176.07 (86.97)

199.25 (92.99)

148.85 (67.16)

180.56 (95.55)

0.48

Sway 1: Sway Velocity

7.72 (2.20)

7.93 (2.14)

7.26 (1.84)

8.01 (2.62)

0.94

Sway 1: Sway Intensity

3.81 (1.05)

3.96 (0.99)

3.56 (0.86)

3.91 (1.30)

0.86

Sway 2: Mean Sway

4.83 (1.55)

5.24 (1.55)

4.37(1.18)

4.87 (1.81)

0.44

Sway 2: Transversal Sway

2.45 (0.99)

2.74 (1.36)

2.22 (0.59)

2.39 (0.85)

0.26

Sway 2: Sagittal Sway

3.62 (1.29)

3.83 (1.25)

3.27 (0.98)

3.77 (1.57)

0.87

250.12 (185.19)

269.9 (150.52)

206.8 (107.18)

274.89 (268.02)

0.95

Sway 2: Sway Velocity

11.34 (3.80)

11.63 (4.10)

11.07 (3.33)

11.32 (4.12)

0.79

Sway 2: Sway Intensity

4.58 (1.25)

4.83 (1.13)

4.47 (1.27)

4.45 (1.38)

0.34

Sway 3: Mean Sway

5.29 (1.76)

5.72 (1.55)

4.56 (1.19)

5.61 (2.25)

0.82

Sway 3: Transversal Sway

2.77 (0.91)

3.02 (0.85)

2.53 (0.75)

2.74 (1.08)

0.32

Sway 3: Sagittal Sway

3.92 (1.53)

4.2 (1.42)

3.25 (0.88)

4.33 (1.95)

0.81

245.07 (167.80)

279.40 (194.86)

194.45 (102.93)

262.(187.07)

0.73

Sway 3: Sway Velocity

8.58 (2.85)

9.03 (2.76)

7.89 (1.98)

8.42 (3.62)

0.82

Sway 3: Sway Intensity

4.31 (1.57)

4.69 (1.69)

3.89 (0.84)

4.36 (1.94)

0.51

Sway 4: Mean Sway

6.32 (1.90)

6.57 (1.83)

6.18 (1.90)

6.20 (2.06)

0.55

Sway 4: Transversal Sway

3.29 (1.17)

3.23 (0.88)

3.49 (1.41)

3.15 (1.17)

0.84

Sway 4: Sagittal Sway

4.69 (1.59)

5.05 (1.62)

4.37 (1.36)

4.63 (1.77)

0.40

395.51 (213.56)

383.25 (196.63)

411.5 (220.67)

391.58 (232.98)

0.90

Sway 4: Sway Velocity

13.49 (4.39)

12.76 (4.60)

14.24 (4.62)

13.48 (4.01)

0.60

Sway 4: Sway Intensity

5.50 (1.62)

5.58 (1.80)

5.61 (1.71)

5.30 (1.37)

0.60

Sway 1: Sway Area

Sway 2: Sway Area

Sway 3: Sway Area

Sway 4: Sway Area
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Table 20. Continued
Purdue Pegboard Dom Only

12.54 (1.84)

12.60 (2.35)

12.70 (1.42)

12.31 (1.70)

0.64

Purdue Pegboard NonDom Only

11.95 (1.57)

12.40 (1.82)

11.75 (1.48)

11.68 (1.33)

0.15

Purdue Pegboard Both Hands

9.64 (1.59)

9.65 (2.03)

9.85 (1.22)

9.42 (1.46)

0.67

Purdue Pegboard Average Assembly

21.36 (4.06)

21.25 (4.76)

21.82 (2.53)

20.97 (4.68)

0.84

Dom = Dominant Hand; NonDom = Non-Dominant Hand; P/S = Protonation/Supination; F-Tap = Finger Tap
Bone Mn Tertiles: Tertile 1 = -5.0 – 0.7 g/g; Tertile 2 = 0.7 – 5.1g/g; Tertile 3 = 5.5 – 43.0 g/g
SD = Standard Deviation
N = 58 for CATSYS N=59 for Purdue Pegboard
Bold-face = borderline statistically significantly different at ≤0.06 level between BnMn tertiles
a = statistically significantly different at ≤0.05 level between BnMn tertiles
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Table 21. Spearman Co-efficient (p-value) for the Associations between Covariates, Mn Biomarkers, and Motor Outcomes
Covariates
Age

Education

Mn Biomarkers
Factory

Drinking Status

ln(BnMn)

ln(FMn)

ln(BMn)

Age
Education

-0.08 (0.52)

Factory

-0.16 (0.24)

-0.22 (0.09)

Drinking Status

-0.12 (0.36)

0.07 (0.62)

ln(BnMn)

0.11 (0.40)

0.03 (0.82)

0.23 (0.08)

0.15 (0.24)

ln(FMn)

-0.02 (0.89)

-0.29 (0.02)

0.82 (<0.01) *

0.09 (0.48)

0.41 (<0.01) *

ln(BMn)

-0.02 (0.88)

-0.25 (0.06)

0.29 (0.02)

-0.02 (0.87)

0.19 (0.15)

0.27 (0.04)
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Table 21. Continued
Reaction Time (Dom)

0.26 (0.04)

-0.12 (0.38)

0.03 (0.81)

0.03 (0.80)

0.05 (0.72)

0.06 (0.67)

0.15 (0.27)

Reaction Time (NonDom)

0.10 (0.45)

-0.07 (0.59)

0.05 (0.69)

-0.12 (0.38)

-0.02 (0.90)

0.09 (0.50)

0.11 (0.40)

Max Frequency P/S (Dom)

-0.14 (0.29)

0.17 (0.20)

-0.09 (0.48)

-0.37 (<0.01) *

-0.23 (0.08)

-0.32 (0.01) *

-0.13 (0.31)

Max Frequency P/S (NonDom)

-0.33 (0.01) *

0.01 (0.96)

-0.29 (0.02)

-0.09 (0.47)

0.03 (0.81)

-0.28 (0.03)

-0.14 (0.30)

Max Frequency F-Tap (Dom)

-0.39 (<0.01) *

0.07 (0.60)

0.04 (0.77)

-0.01 (0.97)

-0.07 (0.62)

-0.19 (0.14)

0.19 (0.16)

Max Frequency F-Tap (NonDom)

0.10 (0.44)

0.11 (0.39)

-0.003 (0.98)

-0.13 (0.32)

0.26 (0.04)

-0.06 (0.66)

0.05 (0.70)

Rhythmic Test P/S slow (Dom)

-0.06 (0.63)

-0.16 (0.22)

0.13 (0.32)

0.02 (0.90)

-0.09 (0.48)

0.05 (0.70)

-0.08 (0.53)

Rhythmic Test P/S slow SD (Dom)

-0.18 (0.17)

-0.08 (0.56)

-0.08 (0.52)

0.05 (0.73)

0.06 (0.66)

-0.07 (0.58)

-0.10 (0.43)

Rhythmic Test P/S slow (NonDom)

0.15 (0.25)

-0.38 (<0.01) *

0.09 (0.48)

0.004 (0.97)

-0.22 (0.09)

0.08 (0.55)

-0.13 (0.34)

Rhythmic Test P/S slow SD (NonDom)

-0.16 (0.24)

-0.14 (0.28)

0.01 (0.94)

-0.04 (0.74)

0.11 (0.42)

0.02 (0.91)

-0.05 (0.72)

Rhythmic Test P/S fast (Dom)

-0.02 (0.88)

-0.01 (0.92)

0.30 (0.02)

-0.07 (0.59)

0.01 (0.96)

0.27 (0.04)

-0.11 (0.42)

Rhythmic Test P/S fast SD (Dom)

0.21 (0.11)

-0.24 (0.07)

-0.13 (0.34)

0.11 (0.40)

0.22 (0.09)

0.02 (0.87)

0.16 (0.24)

Rhythmic Test P/S fast (NonDom)

-0.01 (0.91)

0.17 (0.19)

0.19 (0.15)

-0.20 (0.13)

-0.04 (0.77)

0.09 (0.52)

-0.17 (0.20)

Rhythmic Test P/S fast SD (NonDom)

0.15 (0.24)

-0.18 (0.16)

-0.02 (0.90)

-0.04 (0.74)

0.14 (0.29)

0.16 (0.23)

0.004 (0.97)

Rhythmic Test F-Tap slow (Dom)

-0.05 (0.70)

0.05 (0.69)

-0.05 (0.72)

-0.18 (0.18)

-0.21 (0.11)

-0.09 (0.51)

-0.29 (0.03)

Rhythmic Test F-Tap slow SD (Dom)

-0.06 (0.66)

0.08 (0.53)

-0.05 (0.69)

0.18 (0.17)

0.12 (0.34)

0.04 (0.77)

-0.16 (0.23)

Rhythmic Test F-Tap slow (NonDom)

0.04 (0.75)

-0.19 (0.15)

-0.05 (0.72)

-0.13 (0.33)

-0.27 (0.04)

-0.03 (0.84)

-0.29 (0.02)

Rhythmic Test F-Tap slow SD (NonDom)

-0.15 (0.25)

0.02 (0.87)

0.01(0.96)

0.10 (0.43)

-0.06 (0.66)

0.05 (0.69)

-0.06 (0.64)

Rhythmic Test F-Tap fast (Dom)

0.20 (0.14)

0.06 (0.64)

0.25 (0.06)

-0.07 (0.59)

-0.03 (0.83)

0.28 (0.03)

-0.15 (0.25)

Rhythmic Test F-Tap fast SD (Dom)

-0.03 (0.83)

-0.11 (0.39)

-0.01 (0.94)

0.17 (0.19)

-0.10 (0.45)

0.02 (0.91)

0.06 (0.62)

Rhythmic Test F-Tap fast (NonDom)

0.16 (0.22)

0.08 (0.54)

0.12 (0.37)

-0.20 (0.13)

-0.17 (0.20)

0.12 (0.37)

-0.07 (0.58)

Rhythmic Test F-Tap fast SD (NonDom)

-0.11 (0.42)

-0.17 (0.20)

0.01 (0.95)

0.19 (0.16)

0.13 (0.34)

-0.04 (0.77)

0.17 (0.20)
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Table 21. Continued
2

Tremor Intensity Dom (m/s )

0.14 (0.32)

0.18 (0.17)

0.002 (0.99)

0.12 (0.37)

0.17 (0.19)

0.005 (0.97)

-0.20 (0.13)

Center Frequency Dom (Hz)

-0.09 (0.48)

0.12 (0.36)

-0.10 (0.43)

0.33 (0.01) *

0.26 (0.04)

-0.005 (0.97)

-0.14 (0.27)

Harmonic Index Dom

-0.03 (0.81)

-0.22 (0.10)

0.31 (0.02)

-0.06 (0.63)

0.12 (0.38)

0.29 (0.03)

0.18 (0.17)

Tremor SD Dom

0.19 (0.16)

0.11 (0.41)

-0.33 (0.01) *

0.06 (0.62)

-0.18 (0.17)

-0.28 (0.03)

-0.04 (0.75)

Tremor Intensity NonDom (m/s2 )

-0.02 (0.90)

0.12 (0.37)

-0.03 (0.82)

0.21 (0.10)

0.06 (0.64)

-0.06 (0.67)

-0.26 (0.04)

Center Frequency NonDom (Hz)

0.03 (0.80)

-0.05 (0.70)

-0.16 (0.23)

0.001 (0.99)

-0.12 (0.37)

-0.15 (0.24)

-0.30 (0.02)

Harmonic Index NonDom

0.11 (0.42)

0.04 (0.73)

0.08 (0.52)

0.05 (0.68)

0.19 (0.14)

0.24 (0.06)

-0.09 (0.51)

Tremor SD NonDom

0.29 (0.02)

0.07 (0.61)

-0.18 (0.17)

-0.21 (0.11)

-0.17 (0.20)

-0.28 (0.03)

-0.16 (0.23)
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Table 21. Continued
Sway 1: Mean Sway

0.05 (0.68)

0.005 (0.97)

-0.39 (<0.01) *

0.08 (0.55)

-0.16 (0.22)

-0.06 (0.68)

0.14 (0.30)

Sway 1: Transversal Sway

-0.05 (0.72)

0.05 (0.69)

-0.38 (<0.01) *

0.07 (0.61)

-0.12 (0.38)

-0.40 (<0.01) *

0.02 (0.87)

Sway 1: Sagittal Sway

0.07 (0.60)

-0.0002 (1.00)

-0.24 (0.07)

0.04 (0.74)

-0.19 (0.15)

-0.25 (0.06)

-0.07 (0.60)

Sway 1: Sway Area

0.07 (0.59)

0.12 (0.35)

-0.29 (0.03)

0.18 (0.18)

-0.15 (0.26)

-0.35 (<0.01) *

-0.03 (0.83)

Sway 1: Sway Velocity

0.21 (0.11)

0.11 (0.38)

-0.12 (0.37)

0.15 (0.26)

-0.03 (0.82)

-0.22 (0.09)

0.12 (0.34)

Sway 1: Sway Intensity

0.05 (0.68)

0.02 (0.86)

-0.24 (0.07)

0.25 (0.06)

-0.05 (0.69)

-0.19 (0.16)

0.06 (0.63)

Sway 2: Mean Sway

0.03 (0.79)

-0.14 (0.30)

-0.02 (0.85)

0.25 (0.06)

-0.21 (0.11)

-0.12 (0.36)

0.13 (0.34)

Sway 2: Transversal Sway

0.03 (0.82)

-0.09 (0.47)

-0.16 (0.22)

0.02 (0.89)

-0.13 (0.32)

-0.18 (0.16)

0.07 (0.61)

Sway 2: Sagittal Sway

0.09 (0.49)

-0.08 (0.56)

0.05 (0.69)

0.32 (0.01) *

-0.12 (0.36)

-0.02 (0.88)

0.16 (0.21)

Sway 2: Sway Area

0.15 (0.26)

-0.10 (0.44)

-0.08 (0.53)

0.13 (0.34)

-0.17 (0.19)

-0.14 (0.30)

0.17 (0.21)

Sway 2: Sway Velocity

0.28 (0.03)

-0.03 (0.81)

0.09 (0.51)

0.02 (0.89)

-0.06 (0.67)

-0.01 (0.91)

0.32 (0.01) *

Sway 2: Sway Intensity

0.22 (0.10)

0.05 (0.71)

-0.13 (0.32)

0.19 (0.15)

-0.15 (0.26)

-0.16 (0.21)

0.27 (0.03)

Sway 3: Mean Sway

0.10 (0.47)

0.03 (0.80)

-0.21 (0.11)

-0.18 (0.17)

-0.11 (0.41)

-0.22 (0.09)

-0.05 (0.70)

Sway 3: Transversal Sway

-0.05 (0.71)

-0.01 (0.92)

-0.26 (0.05)

-0.18 (0.16)

-0.17 (0.20)

-0.31 (0.02)

-0.12 (0.36)

Sway 3: Sagittal Sway

0.17 (0.19)

0.06 (0.64)

-0.12 (0.35)

-0.12 (0.35)

-0.03 (0.81)

-0.11 (0.40)

-0.02 (0.86)

Sway 3: Sway Area

0.11 (0.38)

0.10 (0.44)

-0.16 (0.23)

-0.09 (0.49)

-0.02 (0.86)

-0.21 (0.11)

0.06 (0.64)

Sway 3: Sway Velocity

0.33 (0.01) *

0.13 (0.33)

-0.13 (0.31)

0.06 (0.66)

0.01 (0.95)

-0.21 (0.11)

0.14 (0.27)

Sway 3: Sway Intensity

0.13 (0.36)

0.15 (0.26)

-0.22 (0.09)

-0.05 (0.72)

-0.11 (0.40)

-0.27 (0.03)

0.11 (0.41)

Sway 4: Mean Sway

-0.02 (0.87)

0.25 (0.06)

0.03 (0.83)

0.10 (0.46)

-0.11 (0.40)

-0.003 (0.98)

-0.08 (0.57)

Sway 4: Transversal Sway

-0.01 (0.92)

0.17 (0.19)

0.09 (0.48)

-0.05 (0.70)

-0.03 (0.81)

0.03 (0.81)

0.06 (0.65)

Sway 4: Sagittal Sway

0.07 (0.59)

0.18 (0.16)

-0.03 (0.81)

0.08 (0.53)

-0.15 (0.27)

-0.02 (0.88)

-0.06 (0.67)

Sway 4: Sway Area

0.13 (0.34)

0.18 (0.18)

0.17 (0.20)

-0.04 (0.77)

-0.02 (0.85)

0.09 (0.49)

0.09 (0.51)

Sway 4: Sway Velocity

0.32 (0.01) *

0.06 (0.63)

0.19 (0.16)

-0.14 (0.29)

0.07 (0.62)

0.14 (0.30)

0.17 (0.21)

Sway 4: Sway Intensity

0.21 (0.11)

0.05 (0.73)

0.08 (0.52)

-0.02 (0.87)

-0.06 (0.66)

0.03 (0.81)

0.20 (0.13)
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Purdue Pegboard Dom Only

-0.17 (0.19)

Table 21. Continued
0.30 (0.02)
-0.22 (0.10)

Purdue Pegboard NonDom Only

-0.25 (0.05)

0.07 (0.57)

-0.25 (0.06)

0.03 (0.81)

-0.19 (0.15)

-0.26 (0.04)

0.12 (0.37)

-0.38 (<0.01) *

0.12 (0.36)

-0.12 (0.35)

-0.02 (0.90)

-0.08 (0.54)

-0.16 (0.21)

-0.09 (0.49)

-0.26 (0.05)

0.33 (<0.01) *

-0.33 (0.01) *

-0.04 (0.77)

-0.18 (0.17)

-0.42 (<0.01) *

0.05 (0.70)

Purdue Pegboard Both Hands
Purdue Pegboard Average Assembly

-0.22 (0.10)

-0.08 (0.54)

-0.2 (0.11)

0.07 (0.60)

Dom = Dominant Hand; NonDom = Non-Dominant Hand; P/S = Protonation/Supination; F-Tap = Finger Tap
a = statistically significantly different at ≤0.01 level between BnMn tertiles
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Figure 17. LOWESS Curve of FMn and Max Frequency (NonDom)
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Table 22.  (95% CI) Adjusted Linear Regression Models of Motor Tests with BnMn Splines
Test

Total

BnMn Splines
Low

Medium

High

-0.002 (-0.019, 0.014)

-0.057 (-0.150, 0.036)

-0.003 (-0.033, 0.027)

0.044 (-0.023, 0.113)

-0.004 (-0.019, 0.011)

-0.071 (-0.222, 0.080)

0.061 (-0.045, 0.167)

-0.009 (-0.029, 0.010)

-0.316 (-0.785, 0.152)

0.101 (-1.970, 2.171)

-0.499 (-1.408, 0.410)

0.038 (-2.189, 2.266)

g

0.744 (-1.145, 2.634)

0.337 (-0.384, 1.058)

0.373 (1.407, 2.153)

0.040 (-0.452, 0.532)

0.058 (-3.690, 3.806)

-0.410 (-1.272, 0.453)

1.822 (-0.411, 4.055)

0.350 (-0.217, 0.917)

-0.474 (-1.827, 0.879)

1.145 (-0.229, 2.520)

-0.508 (-3.313, 2.298)

-0.015 (-0.048, 0.017)

-0.049 (-0.119, 0.021)

-0.032 (-0.192, 0.129)

0.029 (-0.056, 0.113)

e

0.012 (-0.004, 0.028)

0.025 (-0.047, 0.097)

-0.009 (-0.048, 0.030)

0.033 (-0.004, 0.071)

Rhythmic Test P/S slow (NonDom) e

-0.023 (-0.050, 0.004)

0.100 (-0.113, 0.313)

-0.057 (-0.115, 0.001)

0.001 (-0.060, 0.063)

Reaction Time (Dom)

d

Reaction Time (NonDom)

Max Frequency P/S (Dom)

d

e

Max Frequency P/S (NonDom)

Max Frequency F-Tap (Dom)

e

0.393 (0.018, 0.768)

e

Max Frequency F-Tap (NonDom)

Rhythmic Test P/S slow (Dom)

e

e

Rhythmic Test P/S slow SD (Dom)
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Table 22. Continued
Rhythmic Test P/S slow SD (NonDom)

Rhythmic Test P/S fast (Dom)

e

e

g

0.017 (-0.002, 0.035)

0.039 (-0.021, 0.100)

-0.023 (-0.076, 0.030)

0.046 (0.001, 0.091)

-0.009 (-0.027, 0.009)

-0.043 (-0.135, 0.048)

0.020 (-0.022, 0.063)

-0.035 (-0.077, 0.007)

e

0.016 (0.0001, 0.031)

g

-0.040 (-0.116, 0.035)

0.015 (-0.014, 0.044)

0.056 (-0.016, 0.127)

Rhythmic Test P/S fast (NonDom)d

-0.019 (-0.036, -0.002)

g

-0.031 (-0.126, 0.063)

-0.004 (-0.043, 0.036)

-0.034 (-0.073, 0.004)

0.012 (-0.003, 0.027)

-0.019 (-0.097, 0.059)

0.013 (-0.023, 0.049)

0.020 (-0.016, 0.055)

-0.009 (-0.042, 0.024)

0.044 (-0.057, 0.144)

-0.083 (-0.151, -0.016)

Rhythmic Test P/S fast SD (Dom)

Rhythmic Test P/S fast SD (NonDom)

e

Rhythmic Test F-Tap slow (Dom) e

g

0.173 (0.021, 0.324)

Rhythmic Test F-Tap slow SD (Dom)

e

0.015 (-0.005, 0.035)

0.045 (- 0.54, 0.144)

-0.034 (-0.080, 0.011)

0.068 (0.023, 0.113)

Rhythmic Test F-Tap slow (NonDom)

e

-0.012 (-0.043 0.019)

0.014 (-0.091, 0.119)

-0.025 (-0.116, 0.067)

-0.013 (-0.090, 0.064)

0.004 (-0.013, 0.022)

0.057 (0.004, 0.109)

-0.014 (-0.032, 0.004)

-0.020 (-0.078, 0.037)

-0.003 (-0.041, 0.036)

-0.045 (-0.133, 0.042)

c

0.001 (-0.012, 0.014)

0.026 (-0.134, 0.187)

0.010 (-0.019, 0.038)

-0.009 (-0.036, 0.018)

Rhythmic Test F-Tap fast (NonDom) e

-0.027 (-0.045, -0.008)

Rhythmic Test F-Tap slow SD (NonDom)
Rhythmic Test F-Tap fast (Dom)

e

e

Rhythmic Test F-Tap fast SD (Dom)

Rhythmic Test F-Tap fast SD (NonDom)

e

0.003 (-0.008, 0.014)

g

g

-0.067 (-0.125, -0.008)

-0.016 (-0.061, 0.029)

-0.069 (-0.115, -0.023)

g

0.029 (-0.022, 0.080)

0.012 (-0.016, 0.041)

g

0.052 (0.014, 0.091)

g

g

-0.063 (-0.106, -0.020)

g

-0.001 (-0.028, 0.025)
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Table 22. Continued
Tremor Intensity Dom (m/s 2 ) d

0.007 (-0.002, 0.016)

0.017 (-0.035, 0.070)

0.006 (-0.011, 0.024)

0.003 (-0.039, 0.046)

g

0.494 (-0.893, 1.881)

0.484 (-0.722, 1.700)

0.375 (-0.645, 1.400)

Harmonic Index Dom e

0.006 (-0.008, 0.022)

0.053 (-0.031, 0.138)

-0.049 (-0.109, 0.010)

0.021 (-0.002, 0.044)

Tremor SD Dom e

-0.172 (-0.437, 0.094)

0.057 (-0.482, 0.596)

-1.015 (-1.781, -0.249)

0.045 (-0.026, 0.114)

0.002 (-0.022, 0.027)

0.015 (-0.010, 0.040)

-0.130 (-0.640, 0.381)

-0.598 (-0.3720, 2.525)

1.402 (-1.429, 4.234)

-0.441 (-1.50, 0.269)

Harmonic Index NonDom e

0.007 (-0.008, 0.022)

0.059 (-0.081, 0.198)

-0.036 (-0.100, 0.028)

0.016 (-0.005, 0.036)

Tremor SD NonDom e

-0.205 (-0.451, 0.041)

-1.281 (-3.450, 0.887)

0.391 (-0.438, 1.219)

-0.388 (-0.754, -0.0004)

Center Frequency Dom (Hz)

e

0.443 (0.029, 0.858)

Tremor Intensity NonDom (m/s 2 ) c

Center Frequency NonDom (Hz)

e

0.011 (0.0001, 0.022)

g

g

1.305 (-0.032, 2.643)

g
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Table 22. Continued
Sway 1: Mean Sway e

Sway 1: Transversal Sway

Sway 1: Sagittal Sway

e

e

Sway 1: Sway Area e

-0.125 (-0.584, 0.333)

-0.896 (-1.984, 0.193)

0.187 (-0.918, 1.293)

0.259 (-0.1998, 2.516)

-0.067 (-0.291, 0.157)

-0.385 (-0.921, 0.151)

0.083 (-0.462, 0.627)

0.034 (-1.077, 1.145)

-0.123 (-0.556, 0.309)

-0.714 (-1.750, 0.321)

0.075 (-0.977, 1.127)

0.285 (-1.862, 2.432)

-20.267 (-50.494, 9.959)

-92.901 (-162.478, -23.325)

3.800 (-66.879, 74.480)

30.885 (-113.375, 175.145)

g

e

-0.080 (-0,869, 0.708)

1.392 (-2.667, 5.451)

-1.180 (-3.064, 0.703)

0.865 (-0.989, 2.720)

Sway 1: Sway Intensity e

0.008 (-0.359, 0.375)

-0.303 (-1.190, 0.584)

0.051 (-0.850, 0.952)

0.392 (-1.447, 2.231)

Sway 2: Mean Sway e

-0.431 (-0.983, 0.120)

-3.451 (-6.128, -0.775)

g

-0.302 (-1.543, 0.940)

0.359 (-0.864, 1.581)

-0.086 (-0.348, 0.175)

-0.621 (-1.233, -0.009)

g

0.139 (-0.487, 0.766)

0.163 (-1.107, 1.433)

-0.36 (-0.82, 0.10)

-3.62 (-5.90, -1.34)

-0.20 (-1.64, 1.24)

0.25 (-0.43, 0.94)

Sway 1: Sway Velocity

Sway 2: Transversal Sway

Sway 2: Sagittal Sway

e

Sway 2: Sway Area b

Sway 2: Sway Velocity

d

Sway 2: Sway Intensity e

d

g

-25.67 (-69.31, 17.96)

48.23 (-293.86, 390.33)

-70.93 (-148.09, 6.23)

108.34 (-76.59, 293.27)

-1.01 (-2.23, 0.21)

-3.61 (-10.18, 2.96)

-0.41 (-4.16, 3.3)

-0.80 (-3.01, 1.40)

-0.37 (-0.81, 0.06)

-1.99 (-4.24, 0.25)

-0.15 (-1.19, 0.89)

-0.16 (-1.18, 0.87)
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Table 22. Continued
Sway 3: Mean Sway

c

Sway 3: Transversal Sway

Sway 3: Sagittal Sway

d

c

Sway 3: Sway Area b

d

Sway 3: Sway Velocity

Sway 3: Sway Intensity a

Sway 4: Mean Sway

e

Sway 4: Transversal Sway

Sway 4: Sagittal Sway

0.38 (-2.26, 3.02)

0.31 (-0.91, 1.53)

-1.50 (-4.18, 1.19)

-0.004 (-0.30, 0.29)

-1.00 (-3.63, 1.62)

0.29 (-0.71, 1.30)

-0.04 (-0.50, 0.43)

-0.02 (-0.53, 0.48)

0.02 (-1.48, 1.52)

0.54 (-0.60, 1.68)

-1.59 (-3.87, 0.70)

8.46 (-29.8, 46.77)

-2.52 (-176.46, 171.41)

35.21 (-72.23, 142.65)

-13.64 (-99.42, 72.14)

-0.45 (-1.31, 0.40)

-1.37 (-5.81, 3.06)

-0.88 (-2.98, 1.23)

0.37 (-1.66, 2.40)

-0.18 (-0.56, 0.21)

-0.47 (-2.15, 1.21)

0.13 (-0.90, 1.17)

-0.39 (-1.24, 0.46)

-0.63 (-1.29, 0.03)

-0.41 (-7.69, -0.55)

g

0.97 (-1.29, 3.23)

-0.75 (-1.83, 0.32)

-0.19 (-0.54, 0.17)

-2.08 (-4.01, -0.15)

g

0.72 (-0.50, 1.94)

-0.28 (-0.86, 0.30)

0.10 (-4.24, 4.44)

-0.49 (-1.49, 0.51)

143.87 (-114.30, 402.05)

-57.73 (-180.66, 65.20)

2.04 (-2.94, 7.01)

-0.92 (-3.29, 1.45)

0.77 (-1.14, 2.68)

-0.51 (-1.42, 0.39)

-0.57 (-1.12, -0.02)

e

g

-46.13 (-121.81, 29.56)

Sway 4: Sway Area e

Sway 4: Sway Velocity

d

-0.07 (-0.67, 0.54)

e

Sway 4: Sway Intensity e

-0.63 (-2.05, 0.80)

-0.47 (-1.02, 0.09)

-1.01 (-2.44, 0.42)

-472.10 (-880.47, -63.73)

-6.00 (-13.87, 1.87)

-3.39 (-6.40, -0.37)

g

g
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Table 22. Continued
Purdue Pegboard Dom Only

f

Purdue Pegboard NonDom Only

Purdue Pegboard Both Hands

f

f

Purdue Pegboard Average Assembly f

0.081 (-0.517, 0.679)

1.598 (-1.552, 4.749)

-0.268 (-1.728, 1.193)

0.053 (-1.344, 1.450)

-0.202 (-0.718, 0.314)

0.361 (-2.279, 2.300)

-0.290 (-1.298, 0.716)

-0.232 (-2.659, 2.195)

-0.006 (-0.529, 0.517)

1.950 (-0.616, 4.516)

0.494 (-0.695, 1.684)

-0.554 (-1.820, 0.713)

-2.392 (-10.069, 5.285)

0.942 (-2.083, 3.968)

-1.212 (-2.350, -0.074)

g

-1.978 (-4.916, 0.960)

Dom = Dominant Hand; NonDom = Non-Dominant Hand; P/S = Protonation/Supination; F-Tap = Finger Tap
Manganese biomarker concentrations natural-log transformed
Adjusted for age (continuous), education (continuous), current factory of employment (dichotomous), and current drinking status (dichotomous)
a N = 54; b N = 55; c N = 56; d N = 57; e N =58; f N =59; g = statistically significant at 0.05 level
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Table 23.  (95% CI) Adjusted Linear Regression Models of Motor Tests with FMn Splines
Test

Reaction Time (Dom)

Total

d

Reaction Time (NonDom)

Max Frequency P/S (Dom)

d

e

Max Frequency F-Tap (Dom)

Low

Medium

High

-0.002 (-0.012, 0.008)

-0.015 (-0.045, 0.015)

-0.001 (-0.019, 0.016)

0.006 (-0.020, 0.002)

0.001 (-0.008, 0.010)

0.003 (-0.014, 0.020)

-0.011 (-0.030, 0.008)

0.015 (-0.007, 0.038)

-0.333 (-1.023, -.357)

-0.255 (-0.983, 0.473)

-0.140 (-0.562, 0.281)

0.056 (-0.544, 0.656)

-0.311 (-0.891, 0.270)

-0.014 (-0.752, 0.723)

-0.380 (-0.652, -0.109)

Max Frequency P/S (NonDom)

e

Rhythmic Test P/S slow (Dom)

g

0.032 (-0.207, 0.271)

e

-0.316 (-0.604, -0.028)

Max Frequency F-Tap (NonDom)

FMn Splines

e

e

-0.517 (-1.015, -0.019)

g

0.532 (-0.189, 1.254)

g

-0.619 (-1.221, - 0.016)

g

g

-0.140 (-0.489, 0.210)

-0.477 (-1.117, 0.162)

0.871 (0.186, 1.558)

-1.265 (-2.092, -0.438)

-0.009 (-0.029, 0.011)

0.035 (-0.025, 0.095)

-0.021 (-0.0056, 0.014)

-0.014 (-0.005, 0.02)

Rhythmic Test P/S slow SD (Dom)

e

-0.001 (-0.011, 0.009)

0.005 (-0.025, 0.036)

-0.006 (-0.024, 0.012)

0.004 (-0.021, 0.030)

Rhythmic Test P/S slow (NonDom)

e

-0.008 (-0.025, 0.008)

0.001 (-0.050, 0.052)

-0.019 (-0.049, 0.010)

0.008 (-0.034, 0.050)

0.001 (-0.011, 0.012)

0.005 (-0.030, 0.040)

-0.012 (-0.032, 0.009)

0.022 (-0.007,0.052)

Rhythmic Test P/S slow SD (NonDom)

e

g
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Rhythmic Test P/S fast (Dom) e

0.0001 (-0.011, 0.011)

0.015 (-0.016, 0.046)

0.013 (-0.005, 0.032)

-0.035 (-0.061, -0.009)

e

0.006 (-0.004, 0.016)

-0.009 (-0.031, 0.014)

-0.0001 (-0.018, 0.018)

0.029 (0.005, 0.053)

Rhythmic Test P/S fast (NonDom)d

-0.007 (-0.018, 0.003)

-0.017 (-0.049, 0.015)

0.003 (-0.015, 0.021)

-0.022 (-0.048, 0.003)

g

0.016 (-0.001, 0.034)

0.004 (-0.015, 0.022)

0.021 (-0.001, 0.044)

-0.005 (-0.025, 0.015)

0.009 (-0.052, 0.069)

-0.030 (-0.065, 0.006)

0.034 (-0.016, 0.085)

Rhythmic Test P/S fast SD (Dom)

Rhythmic Test P/S fast SD (NonDom)

e

0.012 (0.004, 0.021)

Rhythmic Test F-Tap slow (Dom) e

g

Rhythmic Test F-Tap slow SD (Dom)

e

0.006 (-0.006, 0.018)

0.006 (-0.019, 0.031)

-0.008 (-0.034, 0.019)

0.027 (-0.002, 0.002)

Rhythmic Test F-Tap slow (NonDom)

e

0.004 (-0.016, 0.023)

0.006 (-0.033, 0.045)

-0.013 (-0.055, 0.028)

0.026 (-0.024, 0.076)

-0.002 (-0.031, 0.008)

-0.005 (-0.030, 0.021)

-0.001 (-0.022, 0.020)

-0.002 (-0.030, 0.025)

0.005 (-0.006, 0.017)

0.031 (0.011, 0.052)

g

-0.005 (-0.028, 0.017)

-0.007 (-0.034, 0.019)

c

0.004 (-0.003, 0.011)

-0.005 (-0.020, 0.009)

0.009 (-0.006, 0.024)

0.005 (-0.012, 0.023)

Rhythmic Test F-Tap fast (NonDom) e

0.001 (-0.011, 0.013)

0.018 (-0.006, 0.042)

-0.001 (-0.027, 0.0244)

-0.015 (-0.046, 0.016)

-0.004 (-0.010, 0.003)

-0.019 (-0.034, -0.004)

-0.001 (-0.014, 0.011)

0.005 (-0.011, 0.021)

Rhythmic Test F-Tap slow SD (NonDom)

Rhythmic Test F-Tap fast (Dom)

e

Rhythmic Test F-Tap fast SD (Dom)

Rhythmic Test F-Tap fast SD (NonDom)

e

e

g

g
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Tremor Intensity Dom (m/s 2 ) d

0.001 (-0.005, 0.007)

-0.006 (-0.017, 0.006)

0.001 (-0.011, 0.013)

0.009 (-0.006, 0.023)

0.203 (-0.055, 0.462)

1.225 (-0.420, 2.870)

-0.545 (-1.126, 0.036)

0.536 (0.186, 0.887)

Harmonic Index Dom e

0.002 (-0.007, 0.011)

-0.043 (-1.02, 0.015)

0.013 (-0.004, 0.030)

-0.002 (-0.018, 0.013)

Tremor SD Dom e

-0.063 (-0.227, 0.101)

0.525 (-0.525, 1.553)

-0.155 (-0.415, 0.105)

-0.003 (-0.411, 0.406)

Tremor Intensity NonDom (m/s 2 ) c

0.001 (-0.006, 0.007)

-0.008 (-0.022, 0.006)

0.006 (-0.008, 0.021)

0.001 (-0.016, 0.018)

e

-0.091 (-0.403, 0.221)

1.021 (-1.094, 3.136)

-0.519 (-1.266, 0.229)

0.032 (-0.419, 0.482)

0.006 (-0.003, 0.015)

-0.046 (-0.102, 0.010)

0.019 (0.003, 0.035)

g

0.0005 (-0.014, 0.015)

-0.156 (-0.305, -0.008)

0.254 (-0.669, 1.177)

-0.124 (-0.358, 0.109)

-0.341 (-0.708, 0.026)

Center Frequency Dom (Hz)

e

Center Frequency NonDom (Hz)

Harmonic Index NonDom e

Tremor SD NonDom e

g
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Sway 1: Mean Sway e

Sway 1: Transversal Sway

Sway 1: Sagittal Sway

e

e

Sway 1: Sway Area e

e

Sway 1: Sway Velocity

-0.150 (-0.428, 0.128)

-0.134 (-0.690, 0.421)

-0.316 (-0.791, 0.160)

0.542 (-0.780, 1.865)

-0.069 (-0.205, 0.067)

-0.003 (-0.278, 0.271)

-0.0138 (-0.398, 0.121)

-0.001 (-0.468, 0.466)

-0.125 (-0.388, 0.138)

-0.186 (-0.570, 0.198)

-0.304 (-1.063, 0.455)

0.575 (-0.804, 1.954)

-12.726 (-31.194, 5.742)

-8.622 (-35.680, 18.435)

-35.332 (-88.787,

23.832 (-73.287,

18.124)

120.952)

-0.0735 (-1.526, 0.056)

-0.927 (-2.338, 0.484)

0.137 (-1.121, 1.394)

-0.550 (-1.007, -0.092)

g

Sway 1: Sway Intensity e

-0.050 (-0.274, 0.174)

0.005 (-0.365, 0.375)

-0.349 (-0.857, 0.158)

0.735 (-0.387, 1.856)

Sway 2: Mean Sway e

-0.078 (-0.422, 0.266)

-0.306 (-0.766, 0.154)

-0.725 (-1.634, 0.184)

2.491 (0.839, 4.142)

g

-0.002 (-0.163, 0.158)

0.008 (-0.298, 0.314)

-0.318 (-0.647, 0.01)

0.451 (0.055, 0.847)

g

-0.05 (-0.34, 0.23)

-0.25 (-0.78, 0.28)

-0.36 (-0.82, 0.09)

1.78 (0.52, 3.05)

-19.19 (-42.90, 6.52)

-33.00 (-79.77, 13.76)

-37.97 (-76.87, 0.93)

122.16 (5.43, 238.89)

-1.42 (-2.85, 0.01)

-1.18 (-2.72, 0.35)

0.81 (-1.22, 2.85)

-0.40 (-0.92, 0.12)

-0.51 (-1.07, 0.05)

0.51 (-90.17, 1.18)

Sway 2: Transversal Sway

Sway 2: Sagittal Sway

e

Sway 2: Sway Area b

Sway 2: Sway Velocity

d

Sway 2: Sway Intensity e

d

-0.76 (-1.51, -0.02)

-0.19 (-0.46, 0.08)

g

g

g
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Sway 3: Mean Sway

c

Sway 3: Transversal Sway

Sway 3: Sagittal Sway

d

c

Sway 3: Sway Area b

d

Sway 3: Sway Velocity

Sway 3: Sway Intensity a

Sway 4: Mean Sway

e

Sway 4: Transversal Sway

Sway 4: Sagittal Sway

e

Sway 4: Sway Area e

Sway 4: Sway Velocity

e

Sway 4: Sway Intensity e

d

-0.02 (-0.37, 0.32)

0.19 (-0.51, 0.90)

-0.14 (-0.87, 0.59)

-0.08 (-0.97, 0.81)

0.02 (-0.18, 0.21)

0.17 (-0.19, 0.53)

0.04 (-0.35, 0.43)

-0.17 (-0.64, 0.30)

0.01 (-0.27, 0.29)

0.14 (-0.4, 0.73)

-0.15 (-.76, 0.45)

0.11 (-0.62, 0.85)

-3.75 (-25.48, 17.98)

-6.01 (-71.63, 59.61)

1.47 (-36.90, 39.85)

-12.71 (-67.43, 42.00)

-0.49 (-1.00, 0.02)

-0.88 (-1.93, 0.17)

-0.48 (-1.58, 0.62)

-0.08 (-1.41, 1.25)

-0.11 (-0.32, 0.10)

-0.18 (-0.61, 0.24)

-0.09 (-0.54, 0.36)

-0.06 (-0.60, 0.48)

-0.01 (-0.43, 0.40)

0.29 (-0.43, 1.02)

-0.44 (-1.73, 0.85)

-0.04 (-1.19, 1.11)

-0.02 (-0.24, 0.20)

0.07 (-0.37, 0.52)

-0.05 (-0.53, 0.43)

-0.07 (-0.64, 0.51)

-0.01 (-0.36, 0.34)

0.11 (-0.59, 0.82)

-0.01 (-0.77, 0.75)

-0.16 (-1.1, 0.76)

-4.80 (-51.73, 42.12)

30.15 (-50.11, 110.41)

-76.45 (-228.39, 75.49)

12.67 (-117.58, 142.92)

-0.16 (-1.04, 0.72)

-0.15 (-2.03, 1.74)

-0.52 (-2.83, 1.78)

0.07 (-1.46, 1.59)

-0.09 (-0.43, 0.26)

0.14 (-0.44, 0.73)

-0.66 (-1.55, 0.24)

0.45 (-0.80, 1.70)
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Purdue Pegboard Dom Only

f

Purdue Pegboard NonDom Only

Purdue Pegboard Both Hands

f

f

Purdue Pegboard Average Assembly f

0.087 (-0.281, 0.455)

0.389 (-0.360, 1.137)

-0.224 (-1.070, 0.622)

0.166 (-0.687, 1.019)

-0.121 (-0.439, 0.196)

-0.227 (-0.874, 0.420)

-0.248 (-0.942, 0.446)

0.174 (-0.648, 0.995)

-0.067 (-0.388, 0.254)

-0.017 (-0.667, 0.634)

0.195 (-0.503, 0.892)

-0.498 (-1.324, 0.327)

-0.424 (-1.201, 0.352)

-0.014 (-1.590, 1.562)

-0.156 (-1.847, 1.534)

-1.247 (-3.247, 0.753)

Dom = Dominant Hand; NonDom = Non-Dominant Hand; P/S = Protonation/Supination; F-Tap = Finger Tap
Manganese biomarker concentrations natural-log transformed
Adjusted for age (continuous), education (continuous), current factory of employment (dichotomous), and current drinking status (dichotomous)
a N = 54; b N = 55; c N = 56; d N = 57; e N =58; f N =59; g = statistically significant at 0.05 level
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Table 24.  (95% CI) Adjusted Linear Regression models of motor tests with BMn splines
Test

Reaction Time (Dom)

Total

d

Reaction Time (NonDom)

Max Frequency P/S (Dom)

d

e

BMn Splines

Low

Medium

High

0.008 (-0.046, 0.061)

-0.169 (-0.386, 0.049)

0.048 (-0.105, 0.201)

0.056 (-0.081, 0.193)

-0.006 (-0.054, 0.042)

-0.098 (-0.294, 0.098)

-0.017 (-0.155, 0.121)

0.062 (-0.063, 0.187)

-0.067 (-.630, 1.496)

0.873 (-3.046, 4.793)

-1.315 (-3.933, 1.302)

13.035 (-2.746,
28.817)

Max Frequency P/S (NonDom)

e

-0.201 (-1.482, 1.079)

2.002 (-6.456, 10.461)

-0.346 (-2.136, 1.444)

-2.928 (15.937,
10.080)

Max Frequency F-Tap (Dom)

e

Max Frequency F-Tap (NonDom)

e

1.221 (-0.357, 2.800)

0.440 (-5.495, 6.375)

2.568 (-0.148, 5.284)

-6.361 (-15.379, 2.658)

0.141 (-1.746, 2.028)

4.799 (-2.276, 11.875)

-1.110 (-3.836, 1.617)

7.843 (-55.194,
70.880)

Rhythmic Test P/S slow (Dom)

e

Rhythmic Test P/S slow SD (Dom)

e

Rhythmic Test P/S slow (NonDom)

e

Rhythmic Test P/S slow SD (NonDom)

-0.078 (-0.183, 0.027)

0.040 (-0.363, 0.445)

-0.139 (-0.324, 0.046)

0.104 (-0.510, 0.718)

-0.034 (-0.087, 0.019)

-0.071 (-0.271, 0.131)

0.003 (-0.089, 0.095)

-0.214 (-0.520, 0.091)

0.122 (-0.206, 0.450)

-0.161 (-0.312, -0.011)

0.008 (-0.157, 0.173)

0.021 (-0.141, 0.183)

-0.092 (-0.178, -0.005)

e

-0.024 (-0.087, 0.038)

g

g

-0.032 (-0.531, 0.467)

-0.173 (-0.408, 0.062)
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Rhythmic Test P/S fast (Dom)

e

g

-0.061 (-0.118, -0.005)

-0.117 (-0.343, 0.110)

-0.022 (-0.146, 0.103)

-0.121 (-0.31, 0.090)

g

-0.050 (-0.519, 0.420)

0.002 (-0.221, 0.226)

-0.045 (-0.100, 0.010)

-0.068 (-0.183, 0.048)

-0.129 (-0.358, 0.100)

0.125 (-0.090, 0.340)

-0.002 (-0.052, 0.049)

0.045 (-0.061, 0.150)

0.024 (-0.186, 0.235)

-0.145 (-0.342, 0.053)

-0.087 (-0.193, 0.018)

0.181 (-0.214, 0.576)

-0.176 (-0.334, -0.017)

-0.036 (-0.103, 0.031)

-0.038 (-0.182, 0.106)

-0.011 (-0.299, 0.278)

-0.068 (-0.338, 0.202)

-0.069 (-0.328, 0.190)

-0.123 (-0.325, 0.079))

-0.101 (-0.695, 0.493)

-0.040 (-0.099, 0.016)

-0.055 (0.0176, 0.067)

-0.018 (-0.260, 0.224)

-0.036 (-0.0264, 0.191)

-0.055 (-0.114, 0.003)

0.051 (-0.101, 0.204)

-0.115 (-0.266, 0.035)

-0.084 (-0.302, 0.133)

c

-0.007 (-0.045, 0.032)

0.017 (-0.086, 0.119)

0.004 (-0.143, 0.152)

-0.043 (-0.162, 0.076)

Rhythmic Test F-Tap fast (NonDom) e

-0.023 (-0.088, 0.042)

0.113 (-0.130, 0.357)

-0.100 (-0.212, 0.012)

0.237 (-0.134, 0.607)

0.013 (-0.023, 0.048)

0.001 (-0.093, 0.094)

0.076 (-0.016, 0.168)

-0.110 (-0.243, 0.024)

Rhythmic Test P/S fast SD (Dom)

e

0.055 (0.004, 0.106)

Rhythmic Test P/S fast (NonDom)d

Rhythmic Test P/S fast SD (NonDom)

e

Rhythmic Test F-Tap slow (Dom) e

Rhythmic Test F-Tap slow SD (Dom)

e

Rhythmic Test F-Tap slow (NonDom)

e

Rhythmic Test F-Tap slow SD (NonDom)
Rhythmic Test F-Tap fast (Dom)

-0.103 (-0.203, -0.004)

e

e

Rhythmic Test F-Tap fast SD (Dom)

Rhythmic Test F-Tap fast SD (NonDom)

g

e

g

0.095 (0.008, 0.182)

g

0.280 (-0.787, 1.346)
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Tremor Intensity Dom (m/s 2 ) d

-0.025 (-0.055, 0.004)

-0.041 (-0.122, 0.041)

0.018 (-0.095, 0.132)

-0.053 (-0.0133, 0.027)

-0.538 (-1.949, 0.872)

-0.187 (-6.617, 6.243)

0.890 (-6.061, 7.841)

-1.463 (-4.415, 1.488)

Harmonic Index Dom e

0.016 (-0.034, 0.066)

0.059 (-0.147, 0.265)

-0.055 (-0.20, 0.090)

0.084 (-0.046, 0.214)

Tremor SD Dom e

0.288 (-0.593, 1.168)

2.166 (-1.300, 5.631)

0.061 (-1.849, 1.970)

-0.842 (-4.070, 2.385)

Center Frequency Dom (Hz)

e

Tremor Intensity NonDom (m/s 2 ) c

-0.043 (-0.077, -0.009)

g

-0.114 (-0.243, 0.014)

-0.011 (-0.070, 0.047)

-0.118 (-0.313, 0.076)

e

-1.657 (-3.271, -0.043)

g

-.373 (-7.849, 5.103)

-2.019 (-5.88, 1.550)

-0.915 (-6.948, 5.118)

Center Frequency NonDom (Hz)

Harmonic Index NonDom e

-0.023 (-0.072, 0.025)

-0.065 (-0.165, 0.035)

0.061 (-0.080, 0.202)

-0.167 (-0.468, 0.134)

Tremor SD NonDom e

-0.058 (-0.887, 0.771)

0.541 (-1.568, 2.651)

-1.017 (-2.664, 0.630)

3.428 (-1.406, 8.262)
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Sway 1: Mean Sway e

0.718 (-0.776, 2.212)

4.061 (-1.497, 9.620)

-1.293 (-3.836, 1.251)

7.865 (-0.581, 16.312)

0.537 (-0.184, 1.259)

0.876 (-1.859, 3.611)

0.007 (-1.244, 1.259)

3.461 (-0.695, 7.618)

0.376 (-1.043, 1.795)

3.687 (-1.605, 8.980)

-1.508 (-3.930, 0.913)

6.728 (-1.313, 14.770)

70.632 (-28.273, 169.537)

287.291 (-68.856, 643.439)

-93.649 (-256.610, 69.312)

e

1.935 (-0.595, 4.466)

3.743 (-1.448, 8.935)

-2.028 (-9.349, 5.292)

9.278 (-6.327, 24.883)

Sway 1: Sway Intensity e

0.710 (-0.477, 1.898)

2.448 (-2.088, 6.984)

-0.231 (-2.307, 1.844)

3.725 (-3.168, 10.618)

Sway 2: Mean Sway e

1.673 (-0.118, 3.464)

-0.160 (-6.600, 6.281)

0.311 (-2.636, 3.258)

14.374 (4.587, 24.160)

0.586 (-0.257, 1.429)

0.511 (-2.656, 3.678)

-0.012 (-1.458, 1.434)

4.746 (-0.061, 9.554)

1.45 (-0.03, 2.94)

-1.56 (-6.30, 3.51)

0.41 (-1.91, 2.74)

52.92 (-87.94, 193.78)

-124.11 (-834.92, 586.70)

96.10 (-270.72, 462.92)

73.46 (-395.74, 542.66)

Sway 1: Transversal Sway

Sway 1: Sagittal Sway

e

e

Sway 1: Sway Area e

Sway 1: Sway Velocity

Sway 2: Transversal Sway

Sway 2: Sagittal Sway

e

Sway 2: Sway Area b

Sway 2: Sway Velocity

d

Sway 2: Sway Intensity e

d

762.839 (221.668, 1304.011)

14.21 (6.50, 21.91)

e

g

4.82 (1.00, 8.65)

g

-0.67 (-15.14, 13.80)

4.39 (-2.24, 11.03)

18.16 (-3.87, 40.20)

2.07 (0.71, 3.43)

g

-1.39 (-6.25, 3.58)

2.01 (-0.26, 4.28)

9.11 (1.56, 16.66)

g
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Sway 3: Mean Sway

c

Sway 3: Transversal Sway

Sway 3: Sagittal Sway

d

c

Sway 3: Sway Area b

d

Sway 3: Sway Velocity

Sway 3: Sway Intensity a

Sway 4: Mean Sway

e

Sway 4: Transversal Sway

Sway 4: Sagittal Sway

e

Sway 4: Sway Area e

Sway 4: Sway Velocity

e

Sway 4: Sway Intensity e

d

-1.08 (-3.02, 0.85)

0.60 (-9.13, 10.33)

-1.18 (-6.16, 3.79)

-1.89 (-8.29, 4.51)

-0.37 (-1.32, 0.59)

0.26 (-4.29, 4.80)

-1.24 (-2.77, 0.30)

5.03 (-0.34, 10.40)

-0.59 (-2.20, 1.02)

-0.39 (-6.71, 5.93)

0.10 (-44.51, 4.72)

-1.99 (-7.41, 3.43)

-14.06 (-136.77, 108.65)

-221.36 (-519,57, 76.85)

301.17 (-48.05, 650.40)

-316.91 (-811.93, 178.11)

0.95 (-2.02, 3.92)

2.84 (-1.62, 7.30)

-10.88 (-23.35, 1.59)

0.13 (-1.07, 1.33)

-3.15 (-7.55, 1.24)

2.46 (-0.31, 5.24)

0.07 (-2.16, 2.30)

-7.71 (-15.41, -0.01)

0.65 (-0.54, 1.85)

-0.27 (-4.98, 4.44)

0.11 (-1.89, 2.12)

0.08 (-1.79, 1.96)

-5.84 (-12.37, 0.69)

-0.11 (-3.10, 2.88)

12.75 (2.83, 22.68)

160.40 (-87.36, 408.16)

-751.19 (-1572.64, 70.27)

124.65 (-251.22, 500.53)

2149 (901.20, 3397.64)

2.87 (-1.77, 7.51)

-20.62 (-36.92, -4.31)

1.37 (-0.46, 3.21)

-3.83 (-10.62, 2.95)

g

g

1.95 (-1.15, 5.06)

g

-2.76 (-7.48, 1.96)

0.03 (-3.49, 3.55)

8.02 (0.56, 15.48)

21.58 (0.53, 42.63)

15.25 (3.55, 26.95)

g

5.71 (-0.94, 12.37)

g

g

g

13.17 (-11.60, 37.95)

7.46 (-2.86, 17.78)
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Table 24. Continued
Purdue Pegboard Dom Only

f

1.378 (-0.570, 3.326)

-0.511 (-5.558, 4.536)

2.868 (-1.021, 6.757)

-1.219 (-12.789,
10.351)

Purdue Pegboard NonDom Only

Purdue Pegboard Both Hands

f

f

Purdue Pegboard Average Assembly f

1.007 (-0.691, 2.706)

0.342 (-4.186, 4.870)

2361 (-2.054, 6.775)

-1.027 (-7.505, 5.452)

-0.130 (-1.863, 1.602)

2.953 (-3.690, 9.596)

-0.839 (-3.846, 2.169)

-1.184 (-11.298, 8.930)

6.762 (-3.636, 17.160)

1,968 (-6.043, 9.980)

14.901 (-8.935, 38.738)

4.816 (0.800, 8.831)

e

Dom = Dominant Hand; NonDom = Non-Dominant Hand; P/S = Protonation/Supination; F-Tap = Finger Tap
Manganese biomarker concentrations natural-log transformed
Adjusted for age (continuous), education (continuous), current factory of employment (dichotomous), and current drinking status (dichotomous)
a N = 54; b N = 55; c N = 56; d N = 57; e N =58; f N =59; g = statistically significant at 0.05 level
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5.4 Discussion
Bone Mn has been suggested as a possible indicator of decreased motor function in exposed
individuals. The purpose of this study was to assess the relationship between BnMn and motor test
scores, to the best of our knowledge something that has never been done before in such a large study.
Results from this study suggest a non-linear relationship between the Mn biomarkers and many of
the motor outcomes. In a previous study assessing BnMn vs. manual dexterity using the Purdue
Pegboard test, BnMn was significantly associated with decreasing test scores (Wells et al. 2017). In
our study, continuous ln(BnMn) was not significantly associated with decreasing Pegboard scores.
However, once ln(BnMn) was separated into splines, in the highest range of BnMn concentrations
were significantly associated with decreasing Purdue pegboard scores for both hands. Similar nonlinearity was seen in FMn as well as BMn.
The non-linear relationship between Mn and neurological outcomes has been an area of
debate due to the theory that there is a threshold of where no adverse effects are seen due to the
homeostatic nature of Mn (Finley and Santamaria 2005; Santamaria 2008). Using both the
continuous and spline regressions in this study is important because it allows us to fit a linear and
non-linear model to the data. If we just applied a linear regression model to the data, we could have
misrepresented the results and obscured the possibility of a threshold for Mn in this population
(Santamaria 2008).

Non-linear relationships between biomarkers and Mn have previously been

reported in environmental populations (Henn et al. 2010). In 331 full-term, live birth singleton
mother-infant pairs, maternal blood Mn levels were non-linearly associated with low birth weight
(Eum et al. 2014). In a Ohio-based community study, Mn was non-linearly associated with
decreasing IQ scores, with the highest concentrations of Mn having the strongest association with
decreasing scores (Haynes et al. 2015). This study provides evidence of a non-linear relationship in
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an occupational population. Another strength of the study is that we used well established motor
tests. These tests have been used before and have proven their utility in non-English speaking
populations (Cowan 2009; Iwata et al. 2007).
There are limitations to this study. The small population size could have decreased the
statistical power of this study. However, we were still able to see some significant results to suggest
the non-linear relationship between BnMn and motor outcomes. We adjusted for potential covariates
in this study, however they may be other influences on the relationship between BnMn and motor
test scores that we may not have adjusted for. The lack of normative value for this population for
Purdue Pegboard and CATSYS scores is also a limitation. We are unable to definitively determine
whether there was any abnormality in the motor issues of this population. Future work should assess
the possible non-linear relationship between Mn and health outcomes, specifically motor outcomes.
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CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS

6.1 Overall Study Summary
For various reasons already discussed, current biomarkers do not usefully describe
cumulative Mn exposure. Bone Mn (BnMn) has been suggested as a biomarker of cumulative
Mn exposure due to the Mn body burden found in bone as well as the metal’s relatively long t 1/2
in bone. This cross-sectional study of 60 Chinese male workers assessed the utility of BnMn as a
biomarker of cumulative Mn exposure as well as a predictor of impaired cognitive, olfactory and
motor function.
BnMn, FMn, and BMn were all higher in ferroalloy workers than in manufacturing
workers. This suggests that just like established biomarkers, BnMn is capable of distinguishing
between exposure groups. BnMn in this study population was greater than other studies that have
looked at BnMn in groups. This could be reflective of the increased Mn body burden that our
study population by being occupationally and environmentally exposed to Mn.
Using work history, collected from a questionnaire, we created cumulative exposure
indexes spanning 1) participants entire work history and 2) participants work history since 2000
(~ 15 years previously at the time of the study). BnMn appeared to be significantly associated
with past exposure within the past ~15 – 16 years but not participants’ lifetime occupational
exposure. This suggests that BnMn may be useful as a biomarker of cumulative Mn exposure up
to the previous 15-16 years of exposure.
We utilized a neurological test battery of well-established cognitive, olfactory and motor
tests. BnMn was significantly associated with several cognitive outcomes but not olfactory
function. BnMn was linearly associated with decline in some of the motor outcomes. However,
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results suggest that for many of the motor outcomes, BnMn may be non-linearly associated with
motor function.
6.2 Future Directions
Evidence in this study suggests that BnMn is a useful biomarker of cumulative Mn
exposure and predictor of neurological impairment. BnMn was able to distinguish between
exposure groups, however a cut-off value between exposure groups has not been established. For
this study, BnMn tertiles were created to assess how outcomes changed as BnMn increased.
Future work should develop cut-off values that differentiate between exposure groups.
Number of participants was a limitation of this study. Future work should conduct a
larger occupational study to assess any BnMn trends that may not have been apparent here due to
the limited statistical power. A cumulative exposure index utilizing air Mn concentrations should
be created to assess BnMn’s ability to reflect cumulative air Mn exposure. Additionally, the
relationship between BnMn and other time points of cumulative exposure should be assessed to
determine the extent of time BnMn can represent in cumulative exposure.
Due to the cross-sectional nature of this study, temporal relationships could not be
confirmed with this study. Although the CEI suggests a long-term relationship between Mn
exposure and BnMn, to further elucidate the temporal relationship, a long-term study follow-up
study of cumulative BnMn and its effects is needed.
Further work is needed to assess the non-linear relationship between BnMn and
outcomes. Results from this study suggest a non-linear relationship between BnMn and motor
outcomes. Follow-up to this study should focus on determining if there is a threshold value for
BnMn which there will be beneficial or no change in outcome below this value and impaired
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function after the value is met. Establishment of a threshold value could be beneficial in creating
a new exposure limit for Mn.
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